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Capuramycin displays narrow spectrum of antibacterial activity by targeting bacterial translocase I 
(MraY). In our program of development of new N-acetylglucosaminephosphotransferase1 (DPAGT1) 
inhibitor, we have identified that a capuramycin phenoxypiperidinylbenzylamide analogue (CPPB) inhibits 
DPAGT1 enzyme with an IC50 value of 200 nM. Despite a strong DPAGT1 inhibitory activity, CPPB does 
not show cytotoxicity against normal cells and a series of cancer cell lines. However, CPPB inhibits 
migrations of several solid cancers including pancreatic cancers that require high DPAGT1 expression in 
order for tumor progression. DPAGT1 inhibition by CPPB leads to a reduced expression level of Snail, but 
does not reduce E-cadherin expression level at the IC50 (DPAGT1) concentration. CPPB displays a strong 
synergistic effect with paclitaxel against growth-inhibitory action of a patient-derived pancreatic 
adenocarcinoma, PD002: paclitaxel (IC50 1.25 M) inhibits growth of PD002 at 0.0024-0.16 M in 
combination with 0.10-2.0 M of CPPB (IC50 35 M). 
INTRODUCTION 
Capuramycin (CAP (1), Figure 1) is a nucleoside antibiotic, which has a narrow-spectrum of activity 
against Gram-positive bacteria including Mycobacterium tuberculosis (Mtb).1-3 To date, medicinal 
chemistry efforts on capuramycin have been focused on developing a new TB drug; new capuramycin 
analogues have been synthesized to improve bacterial phospho-MurNAc-pentapeptide translocase I (MraY 
and MurX for Mycobacterium spp.) enzyme as well as antimycobacterial activities.1,4,5 Somewhat recently, 
the anti-Clostridioides difficile (formerly Clostridium difficile) activity of a capuramycin analogue has been 
reported.6 Capuramycin is a specific inhibitor of MraY with the IC50 value of 0.13 M,7 however, some 
other nucleoside antibiotics (e.g., muraymycin A1 and tunicamycins) display activity against MraY, WecA 
(polyprenyl phosphate-GlcNAc-1-phosphate transferase), and its human homologue, DPAGT1 (N-
acetylglucosaminephosphotransferase1)-type phosphotransferases.8-14 MraY is an essential enzyme for 
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 3 
growth of the vast majority of bacteria that catalyzes the transformation from UDP-MurNAc-pentapeptide 
(Park’s nucleotide) to prenyl-MurNAc-pentapeptide (lipid I).15 WecA catalyzes the transformation from 
UDP-GlcNAc to decaprenyl-P-P-GlcNAc, the first membrane-anchored glycophospholipid that is 
responsible for the biosynthesis of mycolylarabinogalactan in Mycobacterium tuberculosis (Mtb). WecA is 
an essential enzyme for the growth of Mtb and some other bacteria. Biochemical studies of WecA enzyme 
are hampered by lack of selective inhibitor molecules.9 Tunicamycin shows inhibitory activity against these 
phosphotransferases with the IC50 values of 2.9 M (MraY/MurX), 0.15 M (WecA), and 1.5 M 
(DPAGT1).9,10 CPZEN-45, an antimycobacterial MraY inhibitor, was reported to exhibit WecA inhibitory 
activity (IC50 ~0.084 M).16 We showed that 2’O-methyl capuramycin (OM-CAP (2), formerly UT-01320, 
Figure 1) does not exhibit MraY/MurX inhibitory activity, but displays a strong WecA inhibitory activity 
(IC50 0.060 M).1,9 In vitro cytotoxicity of tunicamycin has been documented in a number of articles.17 
Acute toxicity of tunicamycin due to its narrow therapeutic window (LD50: 2.0 mg/kg, LD100: 3.5 mg/kg 
mice, IP) discourages scientists from developing tunicamycin for new antibacterial, antifungal, or anti-
cancer agents.18,19 A large number of scientists believe that cytotoxicity of tunicamycin is attributable to its 
interaction with DPAGT1, which catalyzes the first and rate limiting step in the dolichol-linked 
oligosaccharide pathway in N-linked glycoprotein biosynthesis (Figure 2).10,12 In contrast, OM-CAP (2) 
possesses the same level of DPAGT1 inhibitory activity (IC50 4.5 M) to tunicamycins (IC50 1.5 M), but 
it does not show cytotoxicity against healthy cells (e.g., Vero and HPNE cells) at 50 M and some cancer 
cell lines (e.g., L1210, KB, AsPC-1, PANC-1, LoVo, SK-OV-3) at 10 M. A sharp difference in the 
cytotoxicity profiles between tunicamycins (11, Figure 1) and OM-CAP (2) raises the question of whether 
selective inhibition of DPAGT1 enzyme function in certain cells/organs by small molecules does not cause 
unacceptable level of toxicity against human during chemotherapy. We have recently engineered the 
structure of muraymycin to yield strong DPAGT1 inhibitors; one of these analogues, APPB (12, Figure 1), 
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 4 
showed a promising antiproliferative effect on a series of solid cancer cell lines that required overexpression 
of the DPAGT1 gene in their growth and cancer progression.11,13,14 The design of APPB was originated from 
the discovery of DPAGT1 inhibitors of capuramycin analogues. In this article, we report structure-activity 
relationship (SAR) studies of capuramycin to identify novel DPAGT1 inhibitors, and in vitro anti-invasion 
and anti-metastasis activity of a new capuramycin analogue DPAGT1 inhibitor, CPPB (capuramycin 
phenoxypiperidinylbenzylamide analogue, 5) (Figure 1). A unique synergistic effect was observed against 
a patient-derived pancreatic adenocarcinoma, PD002 in a combination of CPPB with paclitaxel. We 
demonstrated key interactions of CPPB with DPAGT1 via molecular docking studies. Lastly, we report a 
semi-synthetic method to deliver enough CPPB for future in vivo studies.   
 
Insert Figure 1 and Figure2 
 
RESULTS AND DISCUSSION 
Chemistry and Structure activity relationship (SAR). Sankyo (currently Daiichi-Sankyo) and Sequella 
have reported several capuramycin (CAP, 1) analogues that have improved MraY enzyme and bacterial 
growth inhibitory activities.2,3,5,20 Their SAR studies rely on a capuramycin biosynthetic intermediate, A-
500359E, which allows delivery of novel amide molecules (R1 group) having an ester (R2) functional group 
(Figure 3). The capuramycin analogue, SQ992, has an interesting antibacterial characteristic with 
antimycobacterial activity in vivo.21 We have accomplished a total chemical synthesis of capuramycin and 
its analogues.22, To date, we have identified an novel analogue possessing improved MraY inhibitory 
activity, Cap-3-amino-1,4-benzodiazepine-2-one analogue,23 and a selective WecA inhibitor, OM-Cap (2), 
via our total synthetic approach (Figure 3).1,9 Since our first report on a total synthesis of capuramycin, a 
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 5 
few improvements of the synthetic scheme have been made: we introduced acid-cleavable protecting groups 
for the uridine ureido nitrogen (3-postion in a) and primary alcohol (6”-position in c) (Scheme 1).23 The 
MDPM and MTPM groups can simultaneously be removed with 30% TFA to form the key synthetic 
intermediate A for capuramycin. In our on-going SAR of capuramycin, commercially available protecting 
groups (BOM and chloroacetyl groups) for the ureido nitrogen (3-position) and C6’’-alcohol were decided 
to apply in our SAR tactics. Success of hydrogenolytic cleavage of the BOM group and tolerability of the 
chloroacetyl group were difficult to predict in capuramycin synthesis. To establish the new protecting group 
strategy, we first demonstrated the synthesis of iso-capuramycin (I-Cap) (Scheme 2A). Syntheses of all 
building blocks and the experimental procedures for their synthetic steps in Scheme 2 and 3 are summarized 
in Supporting Information (SI). Highlights of syntheses of new capuramycin analogues are illustrated in 
Scheme 2 and 3. The (S)-cyanohydrin 13 was subjected to NIS-AgBF4 promoted -selective mannosylation 
with the thioglycoside 14 to yield the -mannosylated cyanohydrin 15 in 78% yield.22 The cyano group of 
15 was hydrated using HgCl2-aldoxime in aq. EtOH, and the BOM and chloroacetyl groups of the generated 
amide were deprotected stepwisely: dechloroacetylation with thiourea followed by hydrogenation with 10% 
Pd-C in AcOH-iPrOH-THF provided the C6”-free alcohol 16 in 53% overall yield. Oxidation-elimination 
reaction of 16 with SO3•pyridine in a solvent system (CH2Cl2/Et3N/DMSO = 10/2/1) provided the -
unsaturated aldehyde 17 in quantitative yield (determined by 1H NMR analysis). After all volatiles were 
removed, the aldehyde 17 was oxidized to the corresponding carboxylic acid 18 by using NaClO2 in the 
presence of NaH2PO4 and 2-methyl-2-butene.
24 The resulting carboxylic acid 18 was coupled with (2S)-
aminocaprolactam by using a standard peptide-forming reaction condition (HOBt, EDCI, and NMM) to 
yield the coupling product 19 in 70% overall yield from 16. Saponification of 19 by using Et3N in MeOH 
provided I-Cap (3) in quantitative yield. Similarly, dimethyl-capuramycin (DM-CAP) was synthesized in 
31% overall yield from the cyanohydrin-acetonide 20. CAP (1) and its three analogues, OM-CAP (2), I-
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 6 
CAP (3), and DM-CAP (4) were evaluated in enzyme inhibitory assays against bacterial 
phosphotransferases, MraY and WecA, and archaeal and human dolichyl-phosphate GlcNAc-1-
phosphotransferases, AglH and DPAGT1.7,9,11 CAP is a selective MraY inhibitor that does not display 
inhibitory activity against WecA, AglH, and DPAGT1 (Table 1). Previously, OM-CAP (2) was identified 
as a selective WecA inhibitor (IC50 0.060 M) that does not possess MraY inhibitory activity (IC50 >50 M 
(entry 2 in Table 1).9 In this program, it was realized that OM-CAP (2) has inhibitory activity against AglH 
and DPAGT1 with the IC50 values of 2.5 and 4.5 M, respectively (entry 2). I-CAP (3) showed enzyme 
inhibitory activity against MraY, WecA, AglH, and DPAGT1 with the IC50 between 8.5-30 M 
concentrations (entry 3). On the contrary, DM-CAP (4) showed only a weak WecA inhibitory activity (IC50 
35.0 M) (entry 4). In recent reports on co-crystal structures of DAPGT1 with tunicamycin (PDB: 5O5E 
and 6BW6), the fatty acid chain of tunicamycin is occupied in the hydrophobic tunnel (the proposed 
dolichol-phosphate (Dol-P) binding site).25,26 We speculated that introduction of pharmacologically 
amenable hydrophobic groups that occupy the proposed Dol-P binding site is essential to exhibit strong 
DPAGT1 inhibitory activity. In virtual screening of a hydrophobic group (excluding fatty acids) using the 
structure of DPAGT1 with bound tunicamycin (PDB: 6BW6), an analogue (e.g., 
(((trifluoromethoxy)phenoxy)piperidinyl)benzylamide) of (((trifluoromethoxy)phenoxy)piperidin-1-
yl)phenol group (i.e. 34 in Scheme 3) found in a new anti-TB drug, delamanid,27,28 was suggested to be a 
reasonable fatty acid surrogate, whose capuramycin derivatives (capuramycin 
phenoxypiperidinylbenzylamide (CPPB, 5), iso-capuramycin phenoxypiperidinylbenzylamide (I-CPPB, 6), 
O-methyl capuramycin phenoxypiperidinylbenzylamide (OM-CPPB, 7), demethyl capuramycin 
phenoxypiperidinylbenzylamide (DM-CPPB, 8), capuramycin phenoxypiperidinylbenzylamine (CPPA, 9), 
and iso-capuramycin phenoxypiperidinylbenzylamine (I-CPPA, 10)) could bind to DPAGT1 with high 
affinity. However, the docking program used in these studies is not able to distinguish between low- and 
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 7 
high-binding molecules: all (((trifluoromethoxy)phenoxy)piperidin-1-yl)phenyl)methanamino derivatives 
provided “good” GlideScores of between -12.9~-16.6 (see Table S1 in SI). Therefore, we decided to 
synthesize all analogues (CPPB, I-CPPB, OM-CPPB, DM-CPPB, CPPA, and I-CPPA) identified in the 
virtual screening and evaluate their phosphotransferase inhibitory activity.  
The carboxylic acid intermediate 32 for CAP (1) was subjected to peptide coupling reaction with 
(((trifluoromethoxy)phenoxy)piperidin-1-yl)phenyl)methylamine (34), providing the protected CPPB, 37. 
Saponification of 37 and purification by reverse HPLC yielded CPPB (5) in 95% overall yield from 37. 
Similarly, I-CPPB (6), OM-CPPB (7), and DM-CPPB (8) were synthesized from the mannuronic acid 
derivatives 18, 33, and 31 in 24-34% overall yield (Scheme 3A). Capuramycin 
phenoxypiperidinylbenzylamine analogues, CPPA (9) and I-CPPA (10), were synthesized via reductive 
aminations of the aldehydes 29 and 17 with the amine 34, furnishing the desired products in 63-65% overall 
yield from 26 and 16 after saponification. MraY, WecA, AglH, and DPAGT1 enzyme inhibitory activity 
assays for the six (((trifluoromethoxy)phenoxy)piperidin-1-yl)phenyl)methylamine analogues revealed that 
CPPB (5) and I-CPPB (6) are high nM range DPAGT1 inhibitors (entries 5 and 6 in Table 1), however, the 
O-methylation and demethylation analogues (OM-CPPB (7) and DM-CPPB (8)) turned out to be very low- 
or no-DPAGT1 inhibitor (entries 7 and 8). The secondary amine analogues, CPPA (9) and I-CPPA (10), did 
not inhibit all phosphotransferases tested in Table 1 at 50 M concentration (entries 9 and 10). CPPB was 
determined to be three times stronger DAPGT1 inhibitor (IC50 0.20 M) than I-CPPB (entry 5 vs. 6). I-
CPPB did not display MraY inhibitory activity, but showed a very weak WecA and AglH enzyme inhibitory 
activity (entry 6). Interestingly, difference in these phosphotransferase inhibitory profiles between CPPB 
and I-CPPB correlate with their antimycobacterial activity: CPPB possessing MraY/WecA inhibitory 
activity killed Myocobacterium tuberculosis H37Rv, Mycobacterium avium 2285, Mycobacterium 
smegmatis (ATCC607) with the MIC values 6.25-12.5 g/mL. In contrast, I-CPPB, which does not have 
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 8 
MraY inhibitory activity, did not show growth inhibitory activity against these Mycobacterium spp. at 50 
g/mL. 
 
Insert Scheme 1 and Scheme 2 
Insert Table 1 
 
Cytotoxicity of new capuramycin analogues, CPPB (5) and I-CPPB (6). In the capuramycin analogue 
series, the degree of MraY inhibitory activity correlates with their antimycobaterial activity.7-9,13 
Antimycobacterial capuramycin analogues display low in vitro cytotoxicity against mammalian cells, and 
have been recognized as safe drug leads that have acceptable tolerability in animal models.2,3 The toxicity 
of tunicamycin (11, Figure 1) has been studied extensively in vitro: tunicamycin inhibits growth in many 
cancer cell lines without selectivity, and has a narrow therapeutic window demonstrated in in vivo studies 
using mice.18,29 The toxicity of tunicamycin is believed to be attributable to its ability to inhibit DPAGT1 
enzyme function.10,30 However, in our studies, tunicamycin’s toxicity could not be explained solely by its 
inhibition of DPAGT1. Our DPAGT1 inhibitor, APPB (12, Figure 1) inhibits DPAGT1 with greater than 
30-times the inhibitory activity of tunicamycin, and inhibits growth of selected solid cancer cell lines at low 
M concentrations with selective cytotoxicity (IC50 normal cells / cancer cells) of >35.10 The LD50 value of 
APPB is >20 mg/kg (mouse), whereas it is 2.0 mg/kg (mouse) for tunicamycin.10,18 Capuramycin-based 
DPAGT1 inhibitors, CPPB (5) and I-CPPB (6), identified in this program inhibited DPAGT1 enzyme with 
the IC50 values of 0.2 and 0.6 M, respectively. Unlike the MraY-antimycobacterial activity relationship 
observed for CAP analogues, the DPAGT1 inhibitors, CPPB and I-CPPB, did not show antiproliferative 
activity against L1210 (a leukemia cell), HPNE (a normal pancreatic ductal cell), and Vero (a normal kidney 
cell) at 50 M. They showed various levels of growth inhibitory activity against several solid cancer cell 
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lines such as KB (HeLa, a cervix carcinoma), SiHa (a cervical squamous cell carcinoma), HCT-116 (a 
colorectal adenocarcinoma), DLP-1 (a colorectal adenocarcinoma), Capan-1 (a pancreatic ductal 
adenocarcinoma), PANC-1 (a pancreatic ductal carcinoma), AsPC-1 (a pancreatic adenocarcinoma), PD002 
(a patient-derived pancreatic adenocarcinoma) in MTT assays (IC50 15-45 M, Table 2). A lower DPAGT1 
inhibitor, tunicamycin (11), showed growth inhibition of all cell lines in Table 2 with the IC50 values of 
0.78-7.5 M concentrations (entry 5 in Table 2). Cellular behavior and morphological changes of a patient-
derived metastatic pancreatic adenocarcinoma, PD002 treated with CPPB were monitored over time via 
IncuCyte® live cell analysis imaging system (Figure 4A). Interestingly, 10-13% of phase area confluent of 
PD002 culture (time 0h) remained the same after 72h for the CPPB-treated cells (50 M), whereas, ca. 70% 
of confluence was reached for the control PD002 culture (PBS) (Figure 4B vs.4C). Although morphological 
changes were subtle over time (0-72h), cell viability assessed by the MTT reduction assay revealed that 
PD002 cells treated with CPPB (50 M) was significantly decreased (Table 2). Exposure of CPPB (0.2-20 
M) inhibited cell proliferation of PD002: ca. 20% of cell proliferation was inhibited at time 72h. These 
results may indicate that DPAGT1 inhibitors may have cytostatic effect again certain cancerous tumors that 
require DPAGT1 overexpression for their growth. 
 
Insert Table 2 
Insert Figure 4 
 
Cell migratory inhibition by CPPB (5). DPAGT1 catalyzes the first step in N-glycan biosynthesis of 
mammalian cells (Figure 2). Aberrant N-glycosylation is common in many solid cancers and important for 
the epithelial to mesenchymal transition program (EMT, a mechanism of metastases).10 We found high 
levels of DPAGT1 protein expression in a series of pancreatic cancers (e.g., PANC-1, Capan-1, and AsPC-
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1). Dysregulation of DPAGT1 enzyme leads to disturbances in cell-cell adhesions and may increase 
epithelial to mesenchymal transition (EMT): these processes increase migratory and invasive capabilities of 
malignant neoplasms that are the initiation of metastasis in cancer progression, especially pancreatic 
cancer.31,32 Interestingly, there is significant crosstalk between DPAGT1 and the Wnt/-catenin and Snail 
pathway where DPAGT1 overexpression leads to 1) accumulation of -catenin in the cytoplasm and then 
translocation into the nucleus, and 2) reduction of the Snail expression levels, preventing epithelial-
mesenchymal transition by suppressing the E-cadherin expression (a cell-cell adhesion glycoprotein).10,31,32 
As such, aberrations in these pathways occur in numerous cancers, thus, discovery of small molecules 
directed towards inhibition of the Wnt and Snail pathways represents an important area of anticancer 
therapeutics.33-35 In order to obtain insights into anti-metastatic ability of DPAGT1 inhibitors, we explored 
the degree of cell migration in several commercially available cell lines (Capan-1, PANC-1, and AsPC-1), 
a patient-derived pancreatic ductal adenocarcinoma cell line (PD002), a cervical carcinoma (SiHa), and a 
colorectal adenocarcinoma (HCT-116) to determine the effects on cellular motility. After 24h of three 
treatment doses (0.05, 0.1, and 0.2 M) with CPPB (5), inhibition of migration (closing the gap) was 
measured in a scratch assay (wound healing assay).36 Only the images for PD002 are shown in Figure 5 and 
all other images obtained through these experiments are illustrated in Supporting Information (SI). The 
pancreatic cancer cell lines treated with CPPB migrated far less than the PBS treated (control) cells (Figure 
5A-D). In these assays, the wound-healing rate of the untreated PD002 cells was 63% in 24h. In sharp 
contrast, CPPB treated cells inhibited the wound-healing effectively at its IC50 level against DPAGT1 (0.2 
M): the wound-healing rate was approximately 20% (Figure 5B). We thoroughly evaluated migration 
inhibition ability of CPPB compared to gemcitabine, one of the main chemotherapy drugs used to treat 
pancreatic cancer, and tunicamycin using PD002 cells. Gemcitabine shows a wound-healing rate of 43% at 
0.2 M, and tunicamycin shows 35% at 0.2 M (SI). Thus, it was concluded that CPPB is more effective in 
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inhibiting cancer cell migration than gemcitabine and tunicamycin. These trends were further confirmed by 
an endpoint migration assays via Boyden chambers for PD002.37,38 In these assays, the cell migrations of 
PD002 treated with CPPB (0.1 M) were inhibited on a higher level compared to those with tunicamycin 
and gemcitabine at the same concentration (0.1 M) (Figure 6).  
 
Insert Figure 5 
Insert Figure 6 
 
Inhibition of a zinc-finger transcription factor, Snail1 (Snail) in the selected cancer cell lines by 
CPPB. Snail protein is one of the most important transcription factor that induces epithelial to mesenchymal 
transition (EMT), which converts epithelial cells into migratory mesenchymal cells that are more efficient 
at metastasizing.39 EMT induced by overexpression of Snail produces cancer stem-like properties in a 
number of solid organ cancers. Aberrant expression of Snail leads to loss of expression of E-cadherin.40 
Thus, suppression of Snail expression or inhibition of Snail functions represents a potent targeted 
therapeutic strategy for many cancers.41,42 
Immunofluorescence assays using an anti-Snail antibody revealed that the fluorescence intensity of Snail 
was strong in a series of pancreatic cancer cells (PANC-1, AsPC-1, Capan-1, and PD002), and the 
expression of Snail was decreased by the treatment with CPPB in a concentration dependent manner. Among 
pancreatic cancer cell lines, only the data for PD002 and PANC-1 are shown in Figure 7A and 7B (see SI 
for AsPC-1 and Capan-1). The Snail expression level of a non-metastatic pancreatic cancer, PANC-1, was 
much lower than metastatic pancreatic cancers (e.g., PD002 and Capan-1). A few other types of cancer cells 
such as a colorectal cancer (HCT-116) and a cervical cancer (SiHa) were examined by similarly designed 
immunofluorescence assays or Western blot assays (Figures 7C and 7D). The Snail expression in SiHa was 
Page 11 of 74
ACS Paragon Plus Environment
Journal of Medicinal Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
 12 
inhibited by treatment of CPPB in a concentration dependent manner; at the IC50 concentration (0.2 M 
against DPAGT1), CPPB effectively inhibited the Snail expression (Figure 7D). In contrast, the Snail 
expression level in HCT-116 was not noticeably changed by the treatment of CPPB between 0.05 and 2.0 
M concentrations. Interestingly, cell migration of HCT-116 was not inhibited by CPPB demonstrated in 
the wound healing (scratch) assays (Figure 5F). At the concentrations tested in the scratch assays (0.05-2.0 
M), the E-Cadherin expression levels of PD002, PANC-1, and HCT-116 were not changed significantly 
(Figure 8). To support the above discussion based on the immunefluorescent staining (Figure 7 and 8), the 
relative expression levels of Snail and E-cadherin in PD002, PANC-1, and HCT-116 treated with CPPB 
were measured by Western blot analyses (Figure 9). The relative expression levels were obtained by using 
Image Studio™ Lite quantification software, and these quantified data were summarized in SI (see Figure 
S5). PD002 and PANC-1 treated with CPPB (0 to 2.0 M) lead to a dose dependent decrease in Snail. The 
E-Cadherin expression level of a metastatic pancreatic cancer, PD002 was increased in a CPPB 
concentration depended manner (0 to 2.0 M), whereas, a non-metastatic pancreatic cancer, PANC-1 
exhibited the same expression level of E-Cadherin at 0-2.0 M concentrations of CPPB (Figure 9A and 9B). 
A low DPAGT1 expressed-colon cancer, HCT-116 did not display noticeable difference in the expression 
levels of Snail and E-Cadherin at 0-2.0 M CPPB concentrations (Figure 9C).  
 
Insert Figure 7 
Insert Figure 8 
Insert Figure 9 
 
Inhibition of DPAGT1 by CPPB. CPPB decreased the DPAGT1 expression level in all pancreatic cancer 
cell lines examined in Figure 5: the DPAGT1 expression was apparently inhibited by the IC50 concentration 
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of CPPB (0.2 M) (only the data for PD002 and PANC-1 shown Figure 10 and see Figure S4 in SI) for 
AsPC-1 and Capan-1). An important observation is that the DPAGT1 expression of the pancreatic cancer 
cell lines could not completely be inhibited at a high concentration of CPPB (2-20 M) (Figures 9 and 10). 
In MTT assays, we realized that all pancreatic cancers tested remained viable at 20 M concentration of 
CPPB (Table 2). We confirmed that the DPAGT1 expression level in a colorectal adenocarcinoma, HCT-
116 is significantly lower than that in the pancreatic cancer cell lines (PD002 and PANC-1); DPAGT1 was 
not detectable in Western blot assays for the lysate obtained by a standard protocol (50 g/30 L of total 
protein sample). A 10 times concentrated HCT-116 cell lysate (prepared by ultracentrifugation, 130,000xg 
for 1h) enabled us to detect DPAGT1 in Western blotting. By treatment of HCT-116 with CPPB at 0.1-20 
M concentration, the DPAGT1 expression levels of HCT-116 remained higher fluorescence intensity in 
immunefluorescent assay (Figure 10C) and 20-90% in Western blot assays (Figure 9C). These data imply 
that the inhibitory effect of CPPB on cell migration varies depending on degree of inhibition of the DPAGT1 
expression: immunefluorescent assays at 0.2-2.0 M concentrations of CPPB, the degree of DPAGT1 
expression was decreased by the following order: PANC-1 > PD002 >> HCT-116. Migration inhibition 
observed in the scratched assays (Figure 5) is well-correlated with the degree of the DPAGT1 expression 
inhibition. Although CPPB decreased the protein expression of DPAGT1 without significantly decreasing 
its gene (DPAGT1) expression, tunicamycin decreased both the gene expression of DPAGT1 and DPAGT1 
protein expression (Figure 11). These down-regulation in DPAGT1 gene expression by tunicamycin may be 
attributable to its high cytotoxicity against mammalian cells without selectivity.  
 
Insert Figure 10 and Figure 11 
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Synergistic effect of CPPB with paclitaxel. The FOLFIRINOX (a combination of folinic acid, 5-
fluorouracil, irinotecan, and oxaliplatin) and nab-paclitaxel (albumin-bound paclitaxel)-gemcitabine 
regimens have been adopted into clinical practice for patients with metastatic pancreatic cancers.43 Median 
progression-free survival was reported in one study of patients with metastatic pancreatic cancer to be 6.4 
months in the FOLFIRINOX group and 3.3 months in the gemcitabine group.43,44 Over the past years, the 
clinical data have not supported that FOLFIRINOX is associated with any better (or worse) survival rates 
compared to the nab-paclitaxel-gemcitabine regimen as there have been no head-to-head trials.45 However, 
the inclusion of paclitaxel and its derivatives in combination regimens remains an important therapeutic 
strategy in pancreatic cancer chemotherapy since nab-paclitaxel-gemcitabine is associated with less adverse 
effects (toxicity in patients) than FOLFIRINOX.46 In this regard, we were very interested in synergistic or 
additive effects of DPAGT1 inhibitor in combination with paclitaxel. The synergistic or antagonistic 
activities of CPPB were assessed in vitro via checkerboard technique.47,48 In these experiments, CPPB 
displayed strong synergistic effects with paclitaxel in a wide range of concentrations against PD002. Table 
3 summarizes the results of FIC index analyses for selected combinations of CPPB (IC50 35.0 M) plus 
paclitaxel (IC50 1.25 M) that showed synergistic combination (FIC<0.5). The FIC index below 0.50 was 
observed for 20 combinations of two molecules out of 96 different concentrations (see Figure S6 in SI). The 
IC50 value of paclitaxel against PD002 was lowered (0.024-0.61 M) in combination with CPPB (0.1-2.0 
M).  
 
Insert Table 3 
 
Interaction of CPPB with DPAGT1 (Modeling Studies). DPAGT1 encompasses ten transmembrane 
segments, three loops on the ER (endoplasmic reticulum) side, and five loops on the cytoplasmic side. Four 
Page 14 of 74
ACS Paragon Plus Environment
Journal of Medicinal Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
 15 
loops (CL-1, CL-5, CL-7, and CL-9) on the cytoplasmic side form the UDP-GlcNAc-binding domain.25,26 
The hydrophobic tunnel created by the transmembrane segments (TM-4, TM-5 and CL-9) within the lipid 
bilayer is predicted to interact with dolychol-phosphate (Dol-P). The weak DPAGT1 inhibitors, O-methyl 
capuramycin (OM-CAP) and iso-capuramycin (I-CAP) (Table 1), yielded low docking scores (Glide 
Scores) using Schrödinger’s Glide program: the score for OM-CAP was -12.4 and for I-CAP was -10.9. 
These scores predicted that OM-CAP and I-CAP possess significantly lower affinity for DPAGT1 than 
CPPB, which showed a docking score of -16.6 (see Table S1 in SI).49-51 The docked CPPB-DPAGT1 
structure illustrated in Figure 12 shows several key interactions. The C2’-OH acts as a donor in a hydrogen 
bond to the Glu56 carboxylate. This interaction is likely be lost when the C2’-OH is methylated. Pi-stacking 
interactions are observed between 1) Phe249 and the uracil ring, and 2) Trp122 and the 
trifluoromethoxybenzene in the hydrophobic moiety. Asn185 and Ash252 (protonated Asp) form hydrogen-
bond(s) to the primary amide and the dihydropyran-hydroxy (C3”-OH) group, respectively. Additional 
hydrogen-bonds between the uridine ureido group and the backbone amides (Gln44 and Leu46) strengthen 
the ligand interaction. In this program, capuramycin (CAP), a strong MraY inhibitor with no DPAGT1 
inhibitory activity, was successfully engineered to be a relatively strong DPAGT1 inhibitor by introducing 
a hydrophobic functional group, (((trifluoromethoxy)phenoxy) piperidin-1-yl)phenyl)methylamine at the 
C6’’-position. This hydrophobic group allows the preferable conformation of the uridine-
enopyranosiduronic moiety in the DPAGT1 biding domain, resulting in increased interactions with Asn185, 
Ash252, Glu56, and Phe249. 
 
Insert Figure 12 
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A semi-synthesis of CPPB from A500359F. Pharmacological studies of CPPB (5) and its related 
analogues using appropriate animal models will be a focus of our future research efforts. Previously, a 
natural product A-5003659E was used to develop novel capuramycin analogues with strong MraY 
inhibitory activity (Hotoda et. al. 2003) (Figure 3).52 Its free-carboxylic acid analogue, A-500359F was also 
isolated from the capuramycin-producing strain, Streptomyces griseus Sank 60196. Saponification of A-
5003659E to A-500359F was established by the Sankyo group.20 Although, the currently available synthetic 
schemes for capuramycin analogues (e.g., Scheme 3) include a relatively short number of chemical 
steps,22,23,53 a semi-synthetic approach is more feasible to deliver a large quantities of CPPB for 
pharmacological studies. To establish semi-synthesis of CPPB, A-500359F was first synthesized from the 
CAP-synthetic intermediate 32 (Scheme 3A) in a single step. Amide-forming reaction of synthetic A-
500359F with (((trifluoromethoxy)phenoxy) piperidin-1-yl)phenyl)methylamine (34) was performed under 
an optimized condition using EDCI, glyceroacetonide-Oxyma, and NMM in DMF.54 All coupling reagents 
could be removed by partitions between CHCl3 and water and evaporation. The crude product was passed 
through DOWEX 50Wx4 column (MeOH : NH4OH = 4 : 1) to provide CPPB with >95% purity, which was 
further purified by C18-reverse HPLC (MeOH : H2O = 65 : 35) to yield pure CPPB (Scheme 4).  
 
Insert Scheme 4 
 
CONCLUSION 
This paper describes the identification of a new DPAGT1 inhibitor of capuramycin analogue, 
capuramycin phenoxypiperidinylbenzylamide (CPPB, 5) and its isostere I-CPPB (6). Previously, 
tunicamycin is the only DPAGT1 inhibitor that has been widely applied to the studies associated with 
protein misfolding in vitro.55,56 Tunicamycin displays cytotoxicity against cancer and healthy cells with low 
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selectivity ratio.10 One of cytotoxicity mechanisms of tunicamycin is believed to be its ability to inhibit 
DPAGT1 enzyme functions. The DPAGT1 expression levels vary depending on the cell types; renal cancers 
and lymphomas express low-levels of DPAGT1, whereas, a majority of solid cancers express high-levels.57 
Thus, the observed antiproliferative activity of tunicamycin against all types of cancer cells are difficult to 
understand solely by its DPAGT1 inhibitory activity. In our studies, CPPB showed ~7.5 times stronger 
DPAGT1 inhibitory activity than tunicamycin. However, unlike tunicamycin, CPPB did not inhibit growth 
of cancer cell lines at the IC50 values observed for tunicamycin (0.45 -7.5 M). CPPB is a cell-permeable 
molecule which was demonstrated by IncuCyte® live cell analyses and immunofluorescence assays. In this 
article, we have studied effectiveness of CPPB on the expression levels of Snail, E-cadherin, and DPAGT1 
primary in pancreatic cancers (Figures 7-10). CPPB decreased the Snail expression in commercially 
available pancreatic cancer cell lines (PANC-1, AsPC-1, and Capan-1) and a patient-derived pancreatic 
ductal adenocarcinoma cell line (PD002) in a dose dependent manner. On the other hand, the E-cadherin 
expression level was increased in PD002 (a metastatic pancreatic cancer cell) or was not noticeably changed 
in PANC-1 at between 0.05-0.2 M of CPPB. These biochemical data may support that a selective DPAGT1 
inhibitor, CPPB is effective in inhibiting metastasis spread of the pancreatic cancer cells observed in scratch 
and transwell assays (Figures 5 and 6). Other than pancreatic cancers, a lower DPAGT1 expression cell, a 
colorectal adenocarcinoma (HCT-116) and a higher DPAGT1 expression cell, a cervical carcinoma (SiHa) 
were examined. CPPB did not inhibit migration of HCT-116, but strongly inhibited migration of SiHa in 
scratch assays at 0.2 M (IC50 concentration against DPAGT1). These observations were supported by the 
biochemical analyses of the Snail and E-cadherin expression levels. Snail plays an important role in cancer 
progression. The accumulated evidences on Snail indicate that over-expression of Snail promotes drug 
resistance, tumor recurrence and metastasis.40 Although, only limited data have been generated in this 
article, CPPB’s Snail inhibitory activity observed in pancreatic and a several high DPAGT1-expressed cell 
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lines suggests that selective DPAGT1 inhibitors have the potential to develop into less toxic anticancer 
therapeutics than anticancer drugs that are cytotoxic to all dividing cells in the body. CPPB is not cytotoxic 
against a series of cancer and healthy cell lines at 10 M or higher concentrations. However, it showed a 
cytostatic activity against pancreatic cancers and a strong synergistic effect with paclitaxel; cytotoxic 
activity of paclitaxel was improved over 250-times against PD002 in combination with CPPB (0.2-2.0 M). 
Docking studies of CPPB with the available DPAGT1 crystal structures provided insight into unique 
interactions, and thus, structure-based molecule design may be a fruitful approach to improve CPPB’s 
DPAGT1 affinity. A collaboration with Daiichi-Sankyo is essential to efficiently produce CPPB for in vivo 
studies using large-animal models such as dogs, pigs, and monkeys. We have demonstrated a semi-synthesis 
of CPPB from a capuramycin biosynthetic intermediate, A-500359F, that will secure a production of large 
amount of CPPB (Scheme 4). Our total synthetic scheme is amenable to produce gram-quantity of CPPB 
(Scheme 3). Extensive synergistic, toxicity, and pharmacokinetic studies of CPPB will be performed using 
preclinical animal models, and these data including detailed evaluation on in vivo efficacy against pancreatic 
and cervical cancers will be reported elsewhere.  
 
EXPERIMENTAL SECTION 
Chemistry. General Information. All chemicals were purchased from commercial sources and used 
without further purification unless otherwise noted. THF, CH2Cl2, and DMF were purified via Innovative 
Technology's Pure-Solve System. All reactions were performed under an Argon atmosphere. All stirring 
was performed with an internal magnetic stirrer. Reactions were monitored by TLC using 0.25 mm coated 
commercial silica gel plates (EMD, Silica Gel 60F254). TLC spots were visualized by UV light at 254 nm, 
or developed with ceric ammonium molybdate or anisaldehyde or copper sulfate or ninhydrin solutions by 
heating on a hot plate. Reactions were also monitored by using SHIMADZU LCMS-2020 with solvents: A: 
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0.1% formic acid in water, B: acetonitrile. Flash chromatography was performed with SiliCycle silica gel 
(Purasil 60 Å, 230-400 Mesh). Proton magnetic resonance (1H-NMR) spectral data were recorded on 400, 
and 500 MHz instruments. Carbon magnetic resonance (13C-NMR) spectral data were recorded on 100 and 
125 MHz instruments. For all NMR spectra, chemical shifts (δH, δC) were quoted in parts per million (ppm), 
and J values were quoted in Hz. 1H and 13C NMR spectra were calibrated with residual undeuterated solvent 
(CDCl3: δH = 7.26 ppm, δC = 77.16 ppm; CD3CN: δH = 1.94 ppm, δC = 1.32ppm; CD3OD: δH =3.31 ppm, 
δC =49.00 ppm; DMSO-d6: δH = 2.50 ppm, δC = 39.52 ppm; D2O: δH = 4.79 ppm) as an internal reference. 
The following abbreviations were used to designate the multiplicities: s = singlet, d = doublet, dd = double 
doublets, t = triplet, q = quartet, quin = quintet, hept = heptet, m = multiplet, br = broad. Infrared (IR) spectra 
were recorded on a Perkin-Elmer FT1600 spectrometer. HPLC analyses were performed with a Shimadzu 
LC-20AD HPLC system. HR-MS data were obtained from a Waters Synapt G2-Si (ion mobility mass 
spectrometer with nanoelectrospray ionization). All assayed compounds were purified by reverse HPLC to 
be ≥95% purity.  
(2S,3S,4S,5R,6R)-2-((1S)-((2R,5R)-3-Acetoxy-5-(3-((benzyloxy)methyl)-2,4-dioxo-3,4-
dihydropyrimidin-1(2H)-yl)-4-methoxytetrahydrofuran-2-yl)(cyano)methoxy)-6-((2-
chloroacetoxy)methyl)tetrahydro-2H-pyran-3,4,5-triyl triacetate (15). To a stirred suspension of 13 
(0.17 g, 0.38 mmol), 14 (0.37 g, 0.75 mmol), MS3Å (0.50 g) and SrCO3 (0.28 g, 1.88 mmol) in CH2Cl2 (9.4 
mL) were added AgBF4 (0.037 g, 0.19 mmol) and NIS (0.25 g, 1.13 mmol) at 0 °C. After being stirred for 
19h, the reaction mixture was added Et3N (1.0 mL) and passed through a silica gel pad (hexanes/EtOAc = 
1/4). The filtrate was concentrated in vacuo. The crude mixture was purified by silica gel column 
chromatography (hexanes/EtOAc = 2/1 to 1/2) to afford 15 (0.24 g, 78%): 1H NMR (400 MHz, Chloroform-
d) δ 7.40 – 7.27 (m, 6H), 6.07 (d, J = 4.7 Hz, 1H), 6.00 (d, J = 8.2 Hz, 1H), 5.51 (d, J = 9.8 Hz, 1H), 5.47 
(d, J = 9.6 Hz, 1H), 5.37 (dd, J = 3.4, 2.0 Hz, 1H), 5.28 (d, J = 10.2 Hz, 1H), 5.22 – 5.15 (m, 2H), 4.84 (d, 
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J = 3.2 Hz, 1H), 4.71 (s, 2H), 4.41 (dd, J = 5.5, 3.2 Hz, 1H), 4.39 – 4.35 (m, 1H), 4.33 (d, J = 6.0 Hz, 1H), 
4.27 (d, J = 2.3 Hz, 1H), 4.14 (d, J = 1.7 Hz, 2H), 4.03 – 4.01 (m, 1H), 3.93 (ddd, J = 8.9, 5.9, 2.4 Hz, 1H), 
3.47 (s, 3H), 2.20 (s, 3H), 2.19 (s, 3H), 2.07 (s, 3H), 2.02 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 170.20, 
169.84, 169.50, 166.92, 162.19, 150.97, 137.75, 137.46, 128.32 (2C), 127.72, 127.69 (2C), 113.96, 103.58, 
96.29, 88.68, 80.93, 80.09, 72.30, 70.42, 69.60, 68.46, 67.94, 65.16, 64.35, 63.58, 59.26, 40.61, 31.58, 
20.70, 20.66, 20.62, 20.57; HRMS (ESI+) m/z calcd for C35H41ClN3O17 [M + H] 810.2125, found: 810.2151. 
(2R,3S,4S,5R,6R)-2-((1R)-1-((2S,5R)-3-Acetoxy-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-
methoxytetrahydrofuran-2-yl)-2-amino-2-oxoethoxy)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-
triyl triacetate (16). To a stirred solution of 15 (0.24 g, 0.29 mmol) in a 9:1 mixture of EtOH and H2O (2.9 
mL) were added HgCl2 (0.16 g, 0.59 mmol) and acetaldoxime (0.18 mL, 2.9 mmol). After being stirred for 
13h at r.t., the reaction mixture was concentrated in vacuo. The residue was quenched with aq. NaHCO3, 
and extracted with CHCl3. The combined organic extracts were dried over Na2SO4 and concentrated in 
vacuo. The crude product was purified by silica gel column chromatography (hexanes/EtOAc = 1/2 to 
CHCl3/MeOH = 96/4) to afford the amide (0.21 g, 87%). To a solution of the amide (0.21 g, 0.26 mmol) in 
a 1:1 mixture of THF and MeOH (2.6 mL) was added thiourea (0.059 g, 0.77 mmol). After being stirred for 
11h at 50 °C, the reaction mixture was concentrated in vacuo. The residue was diluted with H2O and 
extracted with CHCl3. The combined organic extracts were dried over Na2SO4 and concentrated in vacuo. 
The crude product was purified by silica gel column chromatography (CHCl3/MeOH = 98/2 to 97/3 to 96/4) 
to afford the primary alcohol (0.15 g, 75%). To a stirred solution of the primary alcohol (0.15 g, 0.19 mmol) 
and AcOH (0.040 mL) in a 1:1 mixture of THF and iPrOH (2.0 mL) was added 10% Pd/C (0.12 g) under 
N2. H2 gas was introduced and the reaction mixture was stirred under H2 atmosphere for 3h, the solution 
was filtered through Celite and concentrated in vacuo. The crude product was purified by silica gel column 
chromatography (CHCl3/MeOH = 97/3 to 92/8) to afford 16 (0.10 g, 81%): 
1H NMR (400 MHz, 
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Chloroform-d) δ 9.08 (brs, 1H), 7.60 (d, J = 8.2 Hz, 1H), 6.87 (brs, 1H), 6.12 (brs, 1H), 6.00 (d, J = 8.1 Hz, 
1H), 5.87 (d, J = 3.6 Hz, 1H), 5.55 – 5.52 (m, 1H), 5.26 – 5.22 (m, 2H), 5.20 (t, J = 6.0 Hz, 1H), 5.00 (d, J 
= 1.7 Hz, 1H), 4.53 (dd, J = 6.5, 2.3 Hz, 1H), 4.46 (d, J = 2.3 Hz, 1H), 4.06 (dd, J = 5.5, 3.7 Hz, 1H), 3.76 
– 3.71 (m, 1H), 3.69 – 3.57 (m, 2H), 3.44 (s, 3H), 2.17 (s, 3H), 2.15 (s, 3H), 2.09 (s, 3H), 2.04 (s, 3H); 13C 
NMR (101 MHz, CDCl3) δ 171.42, 170.46, 170.46, 170.40, 163.10, 150.03, 139.50, 103.61, 97.15, 96.95, 
88.50, 81.26, 80.96, 75.33, 72.91, 69.67, 68.89, 65.54, 61.27, 59.05, 50.86, 20.82, 20.75, 20.67, 20.59; 
HRMS (ESI+) m/z calcd for C25H34N3O16 [M + H] 632.1939, found: 632.1963. 
(2S,3S,4S)-3,4-Diacetoxy-2-((1R)-1-((2S,5R)-3-acetoxy-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-
yl)-4-methoxytetrahydrofuran-2-yl)-2-amino-2-oxoethoxy)-3,4-dihydro-2H-pyran-6-carboxylic acid 
(18). To a stirred solution of 16 (0.10 g, 0.16 mmol) and DMSO (0.11 mL, 1.57 mmol) in a 5:1 mixture of 
CH2Cl2 and Et3N (0.80 mL) was added SO3•pyridine (0.25 g, 1.57 mmol). After being stirred for 3h at r.t., 
the reaction mixture was added H2O (0.16 mL) and passed through a silica gel pad (CHCl3/MeOH = 92/8) 
to provide the crude 17. To a stirred solution of the crude mixture in tBuOH (1.0 mL) and 2-methyl-2-butene 
(0.5 mL) was added a solution of NaClO2 (0.071 g, 0.78 mmol) and NaH2PO4•2H2O (0.12 g, 0.78 mmol) in 
H2O (1.0 mL). After being stirred for 4h at r.t., the reaction was quenched with H2O and extracted with 
CHCl3/MeOH (9/1). The combined organic extracts were dried over Na2SO4 and concentrated in vacuo. 
The crude product was purified by silica gel column chromatography (CHCl3/MeOH = 9/1) to afford 18 
(0.078 g, 85%): 1H NMR (400 MHz, Methanol-d4) δ 7.77 (d, J = 8.1 Hz, 1H), 5.94 (d, J = 11.7 Hz, 1H), 
5.94 (s, 1H), 5.78 (t, J = 2.1 Hz, 1H), 5.66 (dd, J = 4.5, 2.5 Hz, 1H), 5.56 (ddd, J = 4.7, 3.2, 1.6 Hz, 1H), 
5.32 (d, J = 3.3 Hz, 1H), 4.99 (t, J = 5.2 Hz, 1H), 4.85 (d, J = 2.1 Hz, 1H), 4.60 (dd, J = 5.2, 2.0 Hz, 1H), 
3.95 (t, J = 5.0 Hz, 1H), 3.39 (s, 3H), 2.13 (s, 3H), 2.08 (s, 3H), 2.05 (s, 3H); 13C NMR (101 MHz, MeOD) 
δ 172.79, 172.06, 171.60, 167.79, 166.01, 152.05, 148.16, 140.97, 104.23, 103.98, 97.91, 88.13, 83.38, 
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82.91, 76.56, 71.95, 65.17, 65.06, 59.41, 20.75, 20.63, 20.57; HRMS (ESI+) m/z calcd for C23H28N3O15 [M 
+ H] 586.1520, found: 586.1549.  
(2S,3S,4S)-2-((1R)-1-((2S,5R)-3-Acetoxy-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-
methoxytetrahydrofuran-2-yl)-2-amino-2-oxoethoxy)-6-(((S)-2-oxoazepan-3-yl)carbamoyl)-3,4-
dihydro-2H-pyran-3,4-diyl diacetate (19). To a stirred solution of 18 (31 mg, 0.053 mmol), 2-(S)-
aminocaprolactam (26 mg, 0.16 mmol), HOBt (21 mg, 0.16 mmol) and NMM (58 L, 0.53 mmol) in DMF 
(0.26 mL) was added EDCI (51 mg, 0.26 mmol). After being stirred for 6h at r.t., the reaction was quenched 
with aq. NaHCO3, and extracted with CHCl3/MeOH (9/1). The combined organic extracts were dried over 
Na2SO4 and concentrated in vacuo. The crude product was purified by silica gel column chromatography 
(CHCl3/MeOH = 95/5) to afford 19 (30 mg, 82%): 
1H NMR (400 MHz, Methanol-d4) δ 7.68 (d, J = 8.2 Hz, 
1H), 6.02 (t, J = 2.1 Hz, 1H), 5.91 (d, J = 4.2 Hz, 1H), 5.89 (d, J = 6.3 Hz, 1H), 5.73 (dd, J = 4.4, 2.5 Hz, 
1H), 5.68 – 5.65 (m, 1H), 5.51 (d, J = 3.0 Hz, 1H), 5.01 (d, J = 4.6 Hz, 1H), 4.76 (d, J = 2.0 Hz, 1H), 4.62 
(d, J = 12.5 Hz, 1H), 4.60 – 4.57 (m, 1H), 3.98 (d, J = 6.1 Hz, 1H), 3.35 (s, 3H), 2.11 (s, 3H), 2.08 (s, 3H), 
2.05 (s, 3H), 2.03 – 1.98 (m, 2H), 1.91 – 1.83 (m, 2H), 1.65 – 1.56 (m, 2H), 1.44 – 1.37 (m, 2H); 13C NMR 
(101 MHz, MeOD) δ 176.12, 172.32, 171.66, 171.29, 171.21, 165.96, 160.96, 151.90, 144.61, 141.42, 
106.25, 103.54, 98.81, 88.77, 83.41, 79.28, 77.39, 74.79, 64.91, 64.49, 59.26, 57.36, 53.25, 42.36, 32.19, 
29.75, 28.94, 20.54, 20.41, 20.32; HRMS (ESI+) m/z calcd for C29H38N5O15 [M + H] 696.2364, found: 
696.2391.  
(2S,3S,4S)-2-((1R)-2-Amino-1-((2S,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3-hydroxy-4-
methoxytetrahydrofuran-2-yl)-2-oxoethoxy)-3,4-dihydroxy-N-((S)-2-oxoazepan-3-yl)-3,4-dihydro-
2H-pyran-6-carboxamide (3). A solution of 19 (30 mg, 0.043 mmol) in a 5:1 mixture of MeOH and Et3N 
(0.60 mL) was stirred for 5h at r.t., and concentrated in vacuo. The crude mixture was purified by reverse-
phase HPLC [column: Luna® (C18, 10 m, 100 Å, 250 x 10 mm), solvents: 15:85 MeOH:H2O, flow rate: 
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3.0 mL/min, UV: 254 nm, retention time: 20 min] to afford I-CAP (3, 24 mg, 98%): 1H NMR (400 MHz, 
Methanol-d4) δ 7.92 (d, J = 8.1 Hz, 1H), 6.02 (d, J = 3.8 Hz, 1H), 5.88 (d, J = 5.1 Hz, 1H), 5.74 (d, J = 8.1 
Hz, 1H), 5.23 (d, J = 5.6 Hz, 1H), 4.67 (d, J = 2.0 Hz, 1H), 4.59 – 4.54 (m, 2H), 4.38 (t, J = 4.2 Hz, 1H), 
4.29 (t, J = 5.1 Hz, 1H), 3.98 (t, J = 5.0 Hz, 1H), 3.84 (t, J = 4.6 Hz, 1H), 3.43 (s, 3H), 2.06 – 1.99 (m, 2H), 
1.89 – 1.81 (m, 2H), 1.62 – 1.45 (m, 2H), 1.44 – 1.33 (m, 2H); 13C NMR (101 MHz, MeOD) δ 176.27, 
173.46, 166.15, 161.85, 152.32, 144.23, 141.91, 109.37, 102.82, 101.22, 90.27, 83.49, 81.02, 78.93, 74.54, 
68.51, 63.53, 58.67, 53.35, 42.48, 32.36, 29.91, 29.06; HRMS (ESI+) m/z calcd for C23H32N5O12 [M + H] 
570.2048, found: 570.2071. 
(2S,3S,4S,5R,6R)-2-((S)-((3aR,4R,6R,6aR)-6-(3-((Benzyloxy)methyl)-2,4-dioxo-3,4-
dihydropyrimidin-1(2H)-yl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)(cyano)methoxy)-6-
((2-chloroacetoxy)methyl)tetrahydro-2H-pyran-3,4,5-triyl triacetate (21). To a stirred suspension of 20 
(0.24 g, 0.56 mmol), 14 (0.55 g, 1.12 mmol), MS3Å (0.72 g), and SrCO3 (0.41 g, 2.80 mmol) in CH2Cl2 
(14.0 mL) were added AgBF4 (0.055 g, 0.28 mmol) and NIS (0.25 g, 1.12 mmol) at 0 °C. After being stirred 
for 12h, the reaction mixture was added Et3N (1.0 mL), and passed through a silica gel pad (hexanes/EtOAc 
= 1/4). The filtrate was concentrated in vacuo. The crude mixture was purified by silica gel column 
chromatography (hexanes/EtOAc = 6/4 - 4/6) to afford 21 (0.39 g, 88%): 1H NMR (400 MHz, Chloroform-
d) δ 7.37 – 7.28 (m, 5H), 7.20 (d, J = 8.1 Hz, 1H), 5.82 (d, J = 8.1 Hz, 1H), 5.61 (d, J = 1.6 Hz, 1H), 5.50 
(d, J = 9.8 Hz, 1H), 5.42 (d, J = 9.8 Hz, 1H), 5.35 – 5.27 (m, 1H), 5.23 (dd, J = 10.0, 3.3 Hz, 1H), 5.07 (d, 
J = 1.9 Hz, 1H), 5.00 (d, J = 3.5 Hz, 1H), 4.98 (dd, J = 6.4, 1.6 Hz, 1H), 4.84 (d, J = 7.1 Hz, 1H), 4.69 (s, 
2H), 4.43 (dd, J = 7.1, 3.6 Hz, 1H), 4.20 (dd, J = 12.2, 4.3 Hz, 1H), 4.17 – 4.07 (m, 2H), 4.05 (d, J = 1.6 
Hz, 2H), 3.97 – 3.92 (m, 1H), 2.16 (s, 3H), 2.02 (s, 3H), 1.98 (s, 3H), 1.59 (s, 3H), 1.39 (s, 3H); 13C NMR 
(101 MHz, CDCl3) δ 169.80, 169.57, 169.47, 166.80, 162.08, 150.84, 140.89, 137.67, 128.33 (2C), 127.91, 
127.77, 127.63 (2C), 115.23, 114.72, 102.84, 96.56, 96.30, 86.55, 84.15, 80.95, 72.42, 70.41, 69.41, 68.39 
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(2C), 66.04, 65.35, 62.90, 40.52, 27.03, 25.20, 20.73, 20.64, 20.59; HRMS (ESI+) m/z calcd for 
C35H41ClN3O16 [M + H] 794.2175, found: 794.2198. 
(2R,3S,4S,5R,6R)-2-((R)-2-Amino-1-((3aR,4S,6R,6aR)-6-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-
yl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)-2-oxoethoxy)-6-(hydroxymethyl)tetrahydro-
2H-pyran-3,4,5-triyl triacetate (22). To a stirred solution of 21 (0.39 g, 0.49 mmol) in a 9:1 mixture of 
EtOH and H2O (4.9 mL) were added HgCl2 (0.27 g, 0.98 mmol) and acetaldoxime (0.30 mL, 4.9 mmol). 
After being stirred for 12h at r.t., the reaction mixture was concentrated in vacuo. The residue was diluted 
with aq.NaHCO3, and extracted with CHCl3. The combined organic extracts were dried over Na2SO4 and 
concentrated in vacuo. The crude product was purified by silica gel column chromatography 
(hexanes/EtOAc = 1/2 to CHCl3/MeOH = 97/3) to afford the amide (0.36 g, 91%). To a solution of the 
amide (0.36 g, 0.45 mmol) in a 1:1 mixture of THF and MeOH (4.5 mL) was added thiourea (0.10 g, 1.34 
mmol). After being stirred for 11h at 50 °C, the reaction mixture was concentrated in vacuo. The residue 
was diluted with H2O, and extracted with CHCl3. The combined organic extracts were dried over Na2SO4 
and concentrated in vacuo. The crude product was purified by silica gel column chromatography 
(CHCl3/MeOH = 98/2 to 97/3 to 96/4) to afford the primary alcohol (0.25 g, 76%). To a stirred solution of 
the alcohol (0.25 g, 0.34 mmol) and AcOH (0.08 mL) in a 1:1 mixture of THF and iPrOH (4.0 mL) was 
added 10% Pd/C (0.20 g) under N2. H2 gas was introduced and the reaction mixture was stirred under H2 
atmosphere. After being stirred for 4h at r.t., the reaction mixture was filtered through Celite and 
concentrated in vacuo. The crude product was purified by silica gel column chromatography (CHCl3/MeOH 
= 96/4 to 92/8) to afford 22 (0.17 g, 80%): 1H NMR (400 MHz, Chloroform-d) δ 9.45 (brs, 1H), 7.34 (d, J 
= 8.0 Hz, 1H), 6.72 (brs, 1H), 6.17 (brs, 1H), 5.78 (d, J = 8.0 Hz, 1H), 5.60 (d, J = 1.7 Hz, 1H), 5.43 (dd, J 
= 10.1, 3.5 Hz, 1H), 5.33 (dd, J = 3.5, 1.7 Hz, 1H), 5.20 (t, J = 10.1 Hz, 1H), 5.12 – 5.05 (m, 1H), 5.03 (dd, 
J = 6.4, 1.7 Hz, 1H), 4.98 (s, 1H), 4.46 (d, J = 5.8 Hz, 1H), 4.33 (t, J = 5.1 Hz, 1H), 3.88 (dt, J = 10.1, 4.0 
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Hz, 1H), 3.60 – 3.53 (m, 2H), 2.14 (s, 3H), 2.07 (s, 3H), 2.02 (s, 3H), 1.55 (s, 3H), 1.35 (s, 3H); 13C NMR 
(101 MHz, CDCl3) δ 170.68, 170.40, 170.28, 170.24, 163.27, 150.13, 142.81, 114.72, 102.85, 96.39, 87.34, 
84.26, 80.35, 71.92, 69.35, 68.64, 66.03, 61.16, 27.25, 25.42, 20.83, 20.77, 20.74; HRMS (ESI+) m/z calcd 
for C25H34N3O15 [M + H] 616.1990, found: 616.2018. 
(2S,3S,4S)-2-((R)-2-Amino-1-((3aR,4S,6R,6aR)-6-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2,2-
dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)-2-oxoethoxy)-6-(((S)-2-oxoazepan-3-yl)carbamoyl)-
3,4-dihydro-2H-pyran-3,4-diyl diacetate (23). To a stirred solution of 22 (0.17 g, 0.27 mmol) and DMSO 
(0.19 mL, 2.72 mmol) in a 5:1 mixture of CH2Cl2 and Et3N (1.4 mL) was added SO3•pyridine (0.43 g, 2.72 
mmol). After being stirred for 3h at r.t., the reaction mixture was added H2O (0.27 mL) and passed through 
a silica gel pad (CHCl3/MeOH = 92/8). To a stirred solution of the crude mixture in 
tBuOH (1.0 mL) and 2-
methyl-2-butene (0.5 mL) was added a solution of NaClO2 (0.12 g, 1.36 mmol) and NaH2PO4•2H2O (0.21 
g, 1.36 mmol) in H2O (1.0 mL). After being stirred for 5h at r.t., the reaction was extracted with 
CHCl3/MeOH (9/1). The combined organic extracts were dried over Na2SO4 and concentrated in vacuo. 
The crude product was purified by silica gel column chromatography (CHCl3/MeOH = 9/1) to afford the 
acid (0.13 g, 81%). To a stirred solution of the acid (28 mg, 0.049 mmol), 2-(S)-aminocaprolactam (24 mg, 
0.15 mmol), HOBt (20 mg, 0.15 mmol) and NMM (54 L, 0.49 mmol) in DMF (0.25 mL) was added EDCI 
(47 mg, 0.25 mmol). After being stirred for 14h at r.t., the reaction was quenched with aq.NaHCO3, and 
extracted with CHCl3/MeOH (9/1). The combined organic extracts were dried over Na2SO4 and 
concentrated in vacuo. The crude product was purified by silica gel column chromatography (CHCl3/MeOH 
= 95/5) to afford 23 (30 mg, 89%): 1H NMR (400 MHz, Methanol-d4) δ 7.79 (d, J = 8.0 Hz, 1H), 5.98 (t, J 
= 2.0 Hz, 1H), 5.84 (d, J = 2.8 Hz, 1H), 5.78 (d, J = 8.0 Hz, 1H), 5.62 (dd, J = 4.5, 2.6 Hz, 1H), 5.51 – 5.48 
(m, 1H), 5.45 (d, J = 3.1 Hz, 1H), 4.74 (d, J = 2.8 Hz, 1H), 4.71 (dd, J = 6.2, 2.9 Hz, 1H), 4.65 (dd, J = 6.2, 
3.3 Hz, 1H), 4.59 – 4.55 (m, 2H), 3.76 – 3.67 (m, 4H), 2.09 (s, 3H), 2.04 (s, 3H), 1.86 (d, J = 13.4 Hz, 3H), 
Page 25 of 74
ACS Paragon Plus Environment
Journal of Medicinal Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
 26 
1.63 – 1.52 (m, 3H), 1.51 (s, 3H), 1.45 – 1.34 (m, 3H), 1.25 (s, 3H); 13C NMR (101 MHz, MeOD) δ 176.35, 
172.24, 171.62, 171.28, 166.24, 161.14, 151.99, 144.75, 142.76, 115.34, 106.38, 102.91, 98.75, 93.55, 
87.12, 85.94, 82.02, 78.13, 67.16, 64.99, 64.46, 56.04, 53.46, 46.10, 42.52, 42.43, 32.25, 29.89, 29.08, 
27.47, 25.47, 20.61, 20.52; HRMS (ESI+) m/z calcd for C29H38N5O14 [M + H] 680.2415, found: 680.2432. 
(2S,3S,4S)-2-((1R)-2-Amino-1-((2S,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3,4-
dihydroxytetrahydrofuran-2-yl)-2-oxoethoxy)-3,4-dihydroxy-N-((S)-2-oxoazepan-3-yl)-3,4-dihydro-
2H-pyran-6-carboxamide (4). A solution of 23 (30 mg, 0.044 mmol) in a 4:1 mixture of TFA and H2O 
(0.88 mL) was stirred for 4h at r.t., and concentrated in vacuo. A solution of the crude diol in a 5:1 mixture 
of MeOH and Et3N (0.88 mL) was stirred for 9h at r.t., filtered, and concentrated in vacuo. The crude mixture 
was purified by reverse-phase HPLC [column: Luna® (C18, 10 m, 100 Å, 250 x 10 mm), solvents: 15:85 
MeOH:H2O, flow rate: 3.0 mL/min, UV: 254 nm, retention time: 16 min] to afford DM-CAP (4, 22 mg, 
90%): 1H NMR (400 MHz, Methanol-d4) δ 7.94 (d, J = 8.1 Hz, 1H), 6.03 (d, J = 4.5 Hz, 1H), 5.85 (d, J = 
3.7 Hz, 1H), 5.73 (d, J = 8.2 Hz, 1H), 5.19 (d, J = 6.7 Hz, 1H), 4.68 (d, J = 1.7 Hz, 1H), 4.61 (dd, J = 11.2, 
1.4 Hz, 1H), 4.54 (dd, J = 5.8, 1.7 Hz, 1H), 4.36 (t, J = 4.5 Hz, 1H), 4.30 (t, J = 5.5 Hz, 1H), 4.12 (t, J = 4.4 
Hz, 1H), 3.97 (t, J = 5.7 Hz, 1H), 3.90 (t, J = 6.5 Hz, 1H), 3.43 – 3.38 (m, 1H), 3.03 (t, J = 7.0 Hz, 1H), 2.70 
– 2.64 (m, 1H), 2.07 – 1.97 (m, 2H), 1.81 (d, J = 15.2 Hz, 2H), 1.62 (q, J = 11.9, 10.7 Hz, 1H), 1.39 (s, 1H); 
13C NMR (101 MHz, MeOD) δ 176.85, 174.05, 166.21, 162.02, 152.21, 144.60, 141.91, 108.72, 102.50, 
101.60, 90.76, 84.77, 79.50, 75.68, 71.40, 63.63, 60.06, 53.44, 42.50, 31.89, 29.82, 29.14; HRMS (ESI+) 
m/z calcd for C22H30N5O12 [M + H] 556.1891, found: 556.1912. 
(2S,3S,4S)-2-((1R)-1-((2S,5R)-4-Acetoxy-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3-
methoxytetrahydrofuran-2-yl)-2-amino-2-oxoethoxy)-6-((4-(4-(4-
(trifluoromethoxy)phenoxy)piperidin-1-yl)benzyl)carbamoyl)-3,4-dihydro-2H-pyran-3,4-diyl 
diacetate (37). To a stirred solution of 32 (55 mg, 0.094 mmol), 34 (0.10 g, 0.28 mmol), HOBt (38 mg, 
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0.28 mmol) and NMM (95 L, 0.94 mmol) in DMF (0.47 mL) was added EDCI (90 mg, 0.47 mmol). After 
being stirred for 7h at r.t., the reaction mixture was quenched with aq.NaHCO3, and extracted with 
CHCl3/MeOH (9/1). The combined organic extracts were dried over Na2SO4 and concentrated in vacuo. 
The crude product was purified by silica gel column chromatography (CHCl3/MeOH = 95/5) to afford 37 
(76 mg, 87%): 1H NMR (400 MHz, Methanol-d4) δ 7.71 (d, J = 8.1 Hz, 1H), 7.23 (d, J = 8.5 Hz, 2H), 7.19 
(d, J = 8.8 Hz, 2H), 7.03 (d, J = 9.1 Hz, 2H), 6.97 (d, J = 8.7 Hz, 2H), 5.97 (t, J = 2.1 Hz, 1H), 5.91 (d, J = 
8.1 Hz, 1H), 5.87 (d, J = 3.8 Hz, 1H), 5.74 (dd, J = 4.5, 2.4 Hz, 1H), 5.67 (ddd, J = 4.5, 2.8, 1.7 Hz, 1H), 
5.43 (d, J = 2.8 Hz, 1H), 5.28 (dd, J = 5.1, 3.8 Hz, 1H), 4.70 (d, J = 1.9 Hz, 1H), 4.54 (dq, J = 7.5, 3.8 Hz, 
1H), 4.42 (d, J = 14.5 Hz, 1H), 4.38 (dd, J = 6.2, 1.9 Hz, 1H), 4.33 (d, J = 14.4 Hz, 1H), 3.82 – 3.79 (m, 
1H), 3.48 (td, J = 9.0, 6.8, 3.5 Hz, 3H), 3.13 – 3.06 (m, 2H), 3.05 (s, 3H), 2.09 (s, 3H), 2.09 (s, 3H), 2.06 (s, 
3H), 1.87 (dtd, J = 12.3, 8.2, 3.6 Hz, 3H); 13C NMR (101 MHz, MeOD) δ 172.85, 171.84, 171.43, 171.17, 
166.07, 162.39, 157.61, 152.11, 151.92, 144.94, 143.92, 141.57, 130.89, 130.02 (2C), 123.59 (2C), 118.04 
(2C), 117.98 (2C), 106.19, 103.75, 98.26, 89.36, 83.17, 78.98, 76.60, 74.71, 73.98, 64.75, 59.35, 48.18, 
48.16, 31.43 (2C), 20.70, 20.52, 20.49; HRMS (ESI+) m/z calcd for C42H47F3N5O16 [M + H] 934.2970, 
found 934.2998. 
(2S,3S,4S)-2-((1R)-2-Amino-1-((2S,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-hydroxy-3-
methoxytetrahydrofuran-2-yl)-2-oxoethoxy)-3,4-dihydroxy-N-(4-(4-(4-
(trifluoromethoxy)phenoxy)piperidin-1-yl)benzyl)-3,4-dihydro-2H-pyran-6-carboxamide (5). A 
solution of 37 (76 mg, 0.082 mmol) in a 5:1 mixture of MeOH and Et3N (1.6 mL) was stirred for 6h at r.t., 
and concentrated in vacuo. The crude mixture was purified by reverse-phase HPLC [column: Luna® (C18, 
10 m, 100 Å, 250 x 10 mm), solvents: 65:35 MeOH:H2O, flow rate: 3.0 mL/min, UV: 254 nm, retention 
time: 18 min] to afford CPPB (5, 63 mg, 95%): 1H NMR (400 MHz, Methanol-d4) δ 7.86 (d, J = 8.1 Hz, 
1H), 7.20 (dd, J = 10.9, 8.6 Hz, 4H), 7.02 (d, J = 9.1 Hz, 2H), 6.97 (d, J = 8.7 Hz, 2H), 5.98 (dd, J = 3.3, 
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1.0 Hz, 1H), 5.80 (d, J = 4.4 Hz, 1H), 5.76 (d, J = 8.2 Hz, 1H), 5.21 (d, J = 4.6 Hz, 1H), 4.68 (d, J = 2.0 Hz, 
1H), 4.54 (dp, J = 7.3, 3.6 Hz, 1H), 4.48 (dd, J = 5.2, 2.0 Hz, 1H), 4.44 (d, J = 14.5 Hz, 1H), 4.39 (t, J = 3.9 
Hz, 1H), 4.33 (d, J = 14.6 Hz, 1H), 4.20 (t, J = 4.7 Hz, 1H), 4.06 – 4.02 (m, 1H), 3.66 (t, J = 5.1 Hz, 1H), 
3.52 – 3.45 (m, 3H), 3.19 (s, 3H), 3.08 (ddd, J = 12.3, 8.6, 3.4 Hz, 3H), 2.15 – 2.07 (m, 2H), 1.86 (dtd, J = 
12.2, 8.3, 3.5 Hz, 3H); 13C NMR (101 MHz, MeOD) δ 173.68, 166.16, 163.31, 157.62, 152.18, 152.08, 
144.15, 141.83, 130.91, 129.76 (2C), 123.58 (2C), 118.03 (4C), 109.58, 102.74, 100.64, 90.83, 83.32, 80.35, 
77.51, 74.27, 74.01, 67.61, 63.48, 58.61, 48.20 (2C), 43.51, 31.47 (2C); HRMS (ESI+) m/z calcd for 
C36H41F3N5O13 [M + H] 808.2653, found 808.2675. 
(2S,3S,4S)-2-((1R)-1-((2S,5R)-3-Acetoxy-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-
methoxytetrahydrofuran-2-yl)-2-amino-2-oxoethoxy)-6-((4-(4-(4-
(trifluoromethoxy)phenoxy)piperidin-1-yl)benzyl)carbamoyl)-3,4-dihydro-2H-pyran-3,4-diyl 
diacetate (35). To a stirred solution of 18 (33 mg, 0.056 mmol), 34 (62 mg, 0.17 mmol), HOBt (23 mg, 
0.17 mmol) and NMM (62 L, 0.56 mmol) in DMF (0.28 mL) was added EDCI (54 mg, 0.28 mmol). After 
being stirred for 14h at r.t., the reaction was quenched with aq.NaHCO3, and extracted with CHCl3/MeOH 
(9/1). The combined organic extracts were dried over Na2SO4 and concentrated in vacuo. The crude product 
was purified by silica gel column chromatography (CHCl3/MeOH = 95/5) to afford 35 (43 mg, 82%): 
1H 
NMR (400 MHz, Methanol-d4) δ 7.69 (d, J = 8.2 Hz, 1H), 7.22 (d, J = 8.5 Hz, 2H), 7.19 (d, J = 8.6 Hz, 2H), 
7.02 (d, J = 9.0 Hz, 2H), 6.98 (d, J = 8.4 Hz, 2H), 5.99 – 5.97 (m, 1H), 5.95 (d, J = 5.8 Hz, 1H), 5.91 (d, J 
= 8.1 Hz, 1H), 5.74 – 5.71 (m, 1H), 5.66 – 5.63 (m, 1H), 5.46 (d, J = 3.2 Hz, 1H), 5.05 (t, J = 4.7 Hz, 1H), 
4.78 (d, J = 2.0 Hz, 1H), 4.57 – 4.52 (m, 1H), 4.49 (d, J = 14.5 Hz, 1H), 4.39 – 4.34 (m, 1H), 4.30 (d, J = 
14.7 Hz, 1H), 3.84 – 3.80 (m, 1H), 3.64 (s, 3H), 3.53 – 3.45 (m, 2H), 3.13 – 3.06 (m, 2H), 2.83 (t, J = 6.5 
Hz, 1H), 2.10 (s, 3H), 2.07 (s, 3H), 2.06 (s, 3H), 1.87 (dtd, J = 12.7, 8.5, 3.5 Hz, 3H); 13C NMR (101 MHz, 
MeOD) δ 172.92, 171.74, 171.36, 170.39, 166.18, 162.23, 157.56, 152.06, 151.81, 145.05, 140.90, 130.78, 
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129.96 (2C), 123.52 (2C), 117.96 (2C), 117.92 (2C), 105.75, 103.47, 98.22, 88.92, 82.72, 78.21, 76.44, 
73.95, 67.92, 64.42, 61.21, 58.65, 58.20, 48.10 (2C), 43.57, 31.38 (2C), 20.60, 20.44, 20.39; HRMS (ESI+) 
m/z calcd for C42H47F3N5O16 [M + H] 934.2970, found 934.2991. 
(2S,3S,4S)-2-((1R)-2-Amino-1-((2S,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3-hydroxy-4-
methoxytetrahydrofuran-2-yl)-2-oxoethoxy)-3,4-dihydroxy-N-(4-(4-(4-
(trifluoromethoxy)phenoxy)piperidin-1-yl)benzyl)-3,4-dihydro-2H-pyran-6-carboxamide (6). A 
solution of 35 (43 mg, 0.046 mmol) in a 5:1 mixture of MeOH and Et3N (0.92 mL) was stirred for 6h at r.t., 
and concentrated in vacuo. The crude mixture was purified by reverse-phase HPLC [column: Luna® (C18, 
10 m, 100 Å, 250 x 10 mm), solvents: 65:35 MeOH:H2O, flow rate: 3.0 mL/min, UV: 254 nm, retention 
time: 19 min] to afford I-CPPB (6, 35 mg, 93%): 1H NMR (400 MHz, Methanol-d4) δ 7.79 (d, J = 8.2 Hz, 
1H), 7.19 (d, J = 8.6 Hz, 4H), 7.02 (d, J = 9.1 Hz, 2H), 6.98 (d, J = 8.5 Hz, 2H), 5.98 (d, J = 3.6 Hz, 1H), 
5.94 (d, J = 5.1 Hz, 1H), 5.77 (d, J = 8.0 Hz, 1H), 5.36 (d, J = 5.8 Hz, 1H), 4.67 – 4.65 (m, 1H), 4.61 (d, J 
= 2.8 Hz, 1H), 4.48 (dd, J = 8.6, 4.6 Hz, 1H), 4.36 – 4.33 (m, 1H), 4.27 (dd, J = 5.4, 2.7 Hz, 1H), 3.71 – 
3.65 (m, 2H), 3.51 (d, J = 4.4 Hz, 2H), 3.48 (s, 3H), 3.25 – 3.18 (m, 2H), 2.13 – 2.00 (m, 3H), 1.92 – 1.76 
(m, 3H); 13C NMR (101 MHz, MeOD) δ 173.68, 166.15, 163.30, 157.62, 152.18, 152.08, 144.15, 141.83, 
130.90, 129.76 (2C), 123.58 (2C), 118.10 (2C), 118.02 (2C), 109.57, 102.73, 100.63, 90.83, 83.32, 80.35, 
77.51, 74.27, 74.01, 67.61, 63.48, 58.61, 48.20 (2C), 43.51, 31.47 (2C); HRMS (ESI+) m/z calcd for 
C36H41F3N5O13 [M + H] 808.2653, found 808.2668. 
(2S,3S,4S)-2-((1R)-2-Amino-1-((2S,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3,4-
dimethoxytetrahydrofuran-2-yl)-2-oxoethoxy)-6-((4-(4-(4-(trifluoromethoxy)phenoxy)piperidin-1-
yl)benzyl)carbamoyl)-3,4-dihydro-2H-pyran-3,4-diyl diacetate (38). To a stirred solution of 33 (38 mg, 
0.068 mmol), 34 (75 mg, 0.20 mmol), HOBt (28 mg, 0.20 mmol) and NMM (75 L, 0.68 mmol) in DMF 
(0.34 mL) was added EDCI (65 mg, 0.34 mmol). After being stirred for 7h at r.t., the reaction was quenched 
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with aq.NaHCO3, and extracted with CHCl3/MeOH (9/1). The combined organic extracts were dried over 
Na2SO4 and concentrated in vacuo. The crude product was purified by silica gel column chromatography 
(CHCl3/MeOH = 95/5) to afford 38 (53 mg, 86%): 
1H NMR (400 MHz, Methanol-d4) δ 7.75 (d, J = 8.2 Hz, 
1H), 7.24 (d, J = 8.6 Hz, 2H), 7.19 (d, J = 8.8 Hz, 2H), 7.02 (d, J = 9.1 Hz, 2H), 6.98 (d, J = 8.5 Hz, 2H), 
5.98 (d, J = 2.0 Hz, 1H), 5.96 (d, J = 8.1 Hz, 1H), 5.85 (d, J = 2.9 Hz, 1H), 5.71 – 5.66 (m, 2H), 5.43 (d, J 
= 2.3 Hz, 1H), 4.70 (d, J = 1.9 Hz, 1H), 4.57 – 4.51 (m, 1H), 4.45 – 4.40 (m, 2H), 4.34 (d, J = 14.4 Hz, 1H), 
3.86 (dd, J = 4.9, 2.9 Hz, 1H), 3.79 (t, J = 6.5 Hz, 1H), 3.60 (dd, J = 6.9, 4.9 Hz, 1H), 3.50 (td, J = 7.6, 7.0, 
3.3 Hz, 2H), 3.46 (s, 3H), 3.11 (dd, J = 8.9, 3.6 Hz, 1H), 3.08 (s, 3H), 2.83 (t, J = 6.5 Hz, 1H), 2.14 (dd, J = 
8.7, 5.4 Hz, 1H), 2.10 (s, 3H), 2.07 (s, 3H), 1.87 (dtd, J = 12.5, 8.2, 3.5 Hz, 2H); 13C NMR (101 MHz, 
MeOD) δ 172.98, 171.81, 171.42, 166.22, 162.30, 157.62, 152.12, 151.87, 145.11, 140.96, 130.85, 130.02 
(2C), 123.58 (2C), 118.03 (2C), 117.98 (2C), 105.81, 103.54, 98.28, 88.98, 82.79, 82.54, 78.28, 76.50, 
74.02, 64.59, 64.49, 61.28, 58.72, 58.27, 48.17 (2C), 43.64, 42.08, 31.45 (2C), 20.67, 20.51; HRMS (ESI+) 
m/z calcd for C41H47F3N5O15 [M + H] 906.3021, found 906.3045. 
(2S,3S,4S)-2-((1R)-2-Amino-1-((2S,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3,4-
dimethoxytetrahydrofuran-2-yl)-2-oxoethoxy)-3,4-dihydroxy-N-(4-(4-(4-
(trifluoromethoxy)phenoxy)piperidin-1-yl)benzyl)-3,4-dihydro-2H-pyran-6-carboxamide (7). A 
solution of 38 (53 mg, 0.059 mmol) in a 5:1 mixture of MeOH and Et3N (1.2 mL) was stirred for 6h at r.t., 
and concentrated in vacuo. The crude mixture was purified by reverse-phase HPLC [column: Luna® (C18, 
10 m, 100 Å, 250 x 10 mm), solvents: 65:35 MeOH:H2O, flow rate: 3.0 mL/min, UV: 254 nm, retention 
time: 21 min] to afford OM-CPPB (7, 46 mg, 96%): 1H NMR (400 MHz, Methanol-d4) δ 7.89 (d, J = 8.1 
Hz, 1H), 7.22 (d, J = 8.4 Hz, 2H), 7.19 (d, J = 8.7 Hz, 2H), 7.02 (d, J = 9.1 Hz, 2H), 6.96 (d, J = 8.5 Hz, 
2H), 5.98 (dd, J = 3.0, 1.2 Hz, 1H), 5.85 (d, J = 3.3 Hz, 1H), 5.76 (d, J = 8.1 Hz, 1H), 5.22 (d, J = 4.1 Hz, 
1H), 4.67 (d, J = 1.9 Hz, 1H), 4.57 – 4.51 (m, 1H), 4.46 (dd, J = 6.8, 2.0 Hz, 1H), 4.43 (d, J = 14.9 Hz, 1H), 
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4.40 (d, J = 3.7 Hz, 1H), 4.32 (d, J = 14.5 Hz, 1H), 4.08 (t, J = 4.2 Hz, 1H), 3.90 (t, J = 4.1 Hz, 1H), 3.70 
(t, J = 5.5 Hz, 1H), 3.52 – 3.47 (m, 2H), 3.45 (s, 3H), 3.13 (s, 3H), 3.08 (td, J = 9.1, 4.6 Hz, 2H), 2.15 – 2.09 
(m, 2H), 1.91 – 1.82 (m, 2H); 13C NMR (101 MHz, MeOD) δ 173.61, 166.17, 163.21, 157.62, 152.09, 
151.92, 144.02, 141.57, 130.94, 129.89 (2C), 123.59 (2C), 118.03 (2C), 117.98 (2C), 109.78, 102.61, 
100.76, 88.94, 83.23, 82.71, 78.58, 77.02, 74.02, 67.27, 63.42, 60.07, 58.70, 58.37, 48.18, 47.87, 45.76, 
43.53, 31.46 (2C); HRMS (ESI+) m/z calcd for C37H43F3N5O13 [M + H] 822.2809, found 822.2838. 
(2S,3S,4S)-2-((R)-2-Amino-1-((3aR,4S,6R,6aR)-6-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2,2-
dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)-2-oxoethoxy)-6-((4-(4-(4-
(trifluoromethoxy)phenoxy)piperidin-1-yl)benzyl)carbamoyl)-3,4-dihydro-2H-pyran-3,4-diyl 
diacetate (36). To a stirred solution of 31 (27 mg, 0.047 mmol), 34 (52 mg, 0.14 mmol), HOBt (19 mg, 
0.14 mmol) and NMM (52 L, 0.47 mmol) in DMF (0.24 mL) was added EDCI (45 mg, 0.24 mmol). After 
being stirred for 11h at r.t., the reaction was quenched with aq.NaHCO3, and extracted with CHCl3/MeOH 
(9/1). The combined organic extracts were dried over Na2SO4 and concentrated in vacuo. The crude product 
was purified by silica gel column chromatography (CHCl3/MeOH = 95/5) to afford 36 (37 mg, 84%): 
1H 
NMR (400 MHz, Methanol-d4) δ 7.69 (d, J = 8.1 Hz, 1H), 7.20 (t, J = 9.5 Hz, 4H), 7.02 (d, J = 9.2 Hz, 2H), 
6.98 (d, J = 8.5 Hz, 2H), 5.99 (t, J = 2.0 Hz, 1H), 5.87 (d, J = 3.0 Hz, 1H), 5.83 (d, J = 8.1 Hz, 1H), 5.66 
(dd, J = 4.4, 2.5 Hz, 1H), 5.57 – 5.54 (m, 1H), 5.41 (d, J = 3.0 Hz, 1H), 4.78 (d, J = 2.3 Hz, 1H), 4.70 (dd, 
J = 6.3, 3.1 Hz, 1H), 4.63 (dd, J = 6.4, 3.5 Hz, 1H), 4.57 – 4.52 (m, 1H), 4.39 (s, 2H), 3.79 (t, J = 6.5 Hz, 
1H), 3.64 (s, 1H), 3.49 (ddd, J = 10.9, 6.4, 3.6 Hz, 2H), 3.09 (ddd, J = 12.4, 8.6, 3.4 Hz, 2H), 2.83 (t, J = 
6.5 Hz, 1H), 2.16 – 2.09 (m, 2H), 2.08 (s, 3H), 2.05 (s, 3H), 1.87 (dtd, J = 12.1, 8.1, 3.5 Hz, 2H), 1.53 (s, 
3H), 1.21 (s, 3H); 13C NMR (101 MHz, MeOD) δ 172.59, 171.76, 171.36, 166.16, 162.38, 157.61, 152.04, 
151.92, 145.03, 142.46, 130.80, 129.66 (2C), 123.59 (2C), 118.05 (2C), 118.02 (2C), 115.67, 106.20, 
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103.33, 98.57, 92.78, 86.55, 85.61, 81.72, 77.88, 73.99, 64.84, 64.58, 61.28, 48.20 (2C), 43.59, 31.47 (2C), 
27.52, 25.45, 20.66, 20.51; HRMS (ESI+) m/z calcd for C42H47F3N5O15 [M + H] 918.3021, found 918.3053. 
(2S,3S,4S)-2-((1R)-2-Amino-1-((2S,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3,4-
dihydroxytetrahydrofuran-2-yl)-2-oxoethoxy)-3,4-dihydroxy-N-(4-(4-(4-
(trifluoromethoxy)phenoxy)piperidin-1-yl)benzyl)-3,4-dihydro-2H-pyran-6-carboxamide (8). A 
solution of 35 (37 mg, 0.040 mmol) in a 4:1 mixture of TFA and H2O (0.80 mL) was stirred for 4h at r.t., 
and concentrated in vacuo. A solution of the crude alcohol in a 5:1 mixture of MeOH and Et3N (0.80 mL) 
was stirred for 10h at r.t., and concentrated in vacuo. The crude mixture was purified by reverse-phase 
HPLC [column: Luna® (C18, 10 m, 100 Å, 250 x 10 mm), solvents: 35:65 MeOH:H2O, flow rate: 3.0 
mL/min, UV: 254 nm, retention time: 15 min] to afford DM-CPPB (8, 29 mg, 91%): 1H NMR (400 MHz, 
Methanol-d4) δ 7.92 (d, J = 8.1 Hz, 1H), 7.20 (d, J = 3.1 Hz, 2H), 7.18 (d, J = 3.5 Hz, 2H), 7.02 (d, J = 9.1 
Hz, 2H), 6.96 (d, J = 8.6 Hz, 2H), 6.01 (d, J = 4.4 Hz, 1H), 5.80 (d, J = 3.0 Hz, 1H), 5.73 (d, J = 8.1 Hz, 
1H), 5.14 (d, J = 6.7 Hz, 1H), 4.66 (d, J = 1.8 Hz, 1H), 4.57 – 4.51 (m, 1H), 4.50 (dd, J = 6.7, 1.7 Hz, 1H), 
4.41 – 4.31 (m, 3H), 4.16 (dd, J = 6.6, 5.0 Hz, 1H), 4.04 (dd, J = 4.9, 3.0 Hz, 1H), 3.88 (dd, J = 6.7, 4.5 Hz, 
1H), 3.47 (t, J = 6.2 Hz, 2H), 3.27 (d, J = 7.2 Hz, 1H), 3.07 (ddd, J = 17.0, 8.1, 4.0 Hz, 2H), 2.37 – 2.29 (m, 
1H), 2.16 – 2.07 (m, 2H), 1.86 (dtd, J = 12.3, 8.2, 3.5 Hz, 2H); 13C NMR (101 MHz, MeOD) δ 174.07, 
170.14, 166.22, 163.14, 157.62, 152.12, 151.99, 144.89, 141.84, 131.07, 129.64 (2C), 123.58 (2C), 118.08 
(2C), 118.03 (2C), 116.78, 108.52, 102.45, 101.32, 91.15, 84.20, 78.81, 75.49, 74.02, 71.19, 69.27, 63.69, 
60.09, 47.81 (2C), 31.46 (2C); HRMS (ESI+) m/z calcd for C35H39F3N5O13 [M + H] 794.2496, found 
794.2522. 
(2R)-2-(((2S,3S,4S)-3,4-Dihydroxy-6-(((4-(4-(4-(trifluoromethoxy)phenoxy)piperidin-1-
yl)benzyl)amino)methyl)-3,4-dihydro-2H-pyran-2-yl)oxy)-2-((2S,5R)-5-(2,4-dioxo-3,4-
dihydropyrimidin-1(2H)-yl)-4-hydroxy-3-methoxytetrahydrofuran-2-yl)acetamide (9). To a stirred 
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solution of 16 (5.8 mg, 0.0092 mmol) and DMSO (0.065 mL, 0.92 mmol) in a 5:1 mixture of CH2Cl2 and 
Et3N (0.5 mL) was added SO3•pyridine (15 mg, 0.092 mmol). After being stirred for 2h at r.t., the reaction 
mixture was added H2O (0.1 mL) and passed through a silica gel pad (CHCl3/MeOH = 93/7) to afford the 
crude 17: this was used without purification. To a stirred solution of the crude 17 and 34 (17 mg, 0.046 
mmol) in CH3CN (0.5 mL) was added NaB(CN)H3 (5.8 mg, 0.092 mol). After being stirred for 3h at r.t., 
the reaction was quenched with aq.NaHCO3, and extracted with CHCl3/MeOH (9/1). The combined organic 
extracts were dried over Na2SO4 and concentrated in vacuo. The crude product was passed through a silica 
gel pad (CHCl3/MeOH = 9/1). The solution of the crude product in a 5:1 mixture of MeOH and Et3N (0.5 
mL) was stirred for 8h at r.t., and concentrated in vacuo. The crude mixture was purified by reverse-phase 
HPLC [column: Luna® (C18, 10 m, 100 Å, 250 x 10 mm), solvents: 65:35 MeOH:H2O, flow rate: 3.0 
mL/min, UV: 254 nm, retention time: 15 min] to afford CPPA (9, 4.6 mg, 65% for 3 steps): 1H NMR (400 
MHz, Methanol-d4) δ 8.02 (d, J = 8.1 Hz, 1H), 7.24 (d, J = 8.5 Hz, 2H), 7.19 (d, J = 8.5 Hz, 2H), 7.03 (d, J 
= 8.9 Hz, 2H), 6.99 (d, J = 8.5 Hz, 2H), 5.90 (d, J = 5.4 Hz, 1H), 5.76 (d, J = 7.8 Hz, 1H), 5.73 (d, J = 8.1 
Hz, 1H), 5.06 (d, J = 6.6 Hz, 1H), 4.57 (dd, J = 6.4, 3.0 Hz, 1H), 4.52 (td, J = 4.4, 1.7 Hz, 1H), 4.33 (t, J = 
5.2 Hz, 1H), 4.26 (d, J = 26.3 Hz, 1H), 4.18 (d, J = 1.6 Hz, 1H), 3.90 – 3.77 (m, 3H), 3.55 – 3.50 (m, 2H), 
3.49 (s, 3H), 3.15 – 3.06 (m, 3H), 2.16 – 2.07 (m, 3H), 1.86 (m, J = 8.8, 4.3 Hz, 3H); 13C NMR (101 MHz, 
MeOD) δ 174.07, 165.86, 163.68, 157.58, 151.26, 144.88, 142.07, 131.25, 129.37 (2C), 123.22 (2C), 118.03 
(4C), 109.57, 102.60, 100.40, 90.92, 83.37, 80.46, 77.56, 74.63, 73.77, 73.15, 67.78, 63.30, 58.33, 48.19 
(2C), 43.21, 30.74 (2C); HRMS (ESI+) m/z calcd for C36H43N3F5O12 [M + H] 794.2860, found 794.2877. 
(2R)-2-(((2S,3S,4S)-3,4-Dihydroxy-6-(((4-(4-(4-(trifluoromethoxy)phenoxy)piperidin-1-
yl)benzyl)amino)methyl)-3,4-dihydro-2H-pyran-2-yl)oxy)-2-((2S,5R)-5-(2,4-dioxo-3,4-
dihydropyrimidin-1(2H)-yl)-3-hydroxy-4-methoxytetrahydrofuran-2-yl)acetamide (10). To a stirred 
solution of 26 (4.6 mg, 0.0073 mmol) and DMSO (0.052 mL, 0.73 mmol) in a 5:1 mixture of CH2Cl2 and 
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Et3N (0.5 mL) was added SO3•pyridine (12 mg, 0.073 mmol). After being stirred for 2h at r.t., the reaction 
mixture was added H2O (0.1 mL) and passed through a silica gel pad (CHCl3/MeOH = 93/7) to afford the 
crude 29. To a stirred solution of the crude 29 and 34 (13 mg, 0.036 mmol) in CH3CN (0.5 mL) was added 
NaB(CN)H3 (4.6 mg, 0.073 mol). After being stirred for 3h at r.t., the reaction was quenched with 
aq.NaHCO3, and extracted with CHCl3/MeOH (9/1). The combined organic extracts were dried over 
Na2SO4 and concentrated in vacuo. The crude product was passed through a silica gel pad (CHCl3/MeOH 
= 9/1). A solution of the crude product in a 5:1 mixture of MeOH and Et3N (0.5 mL) was stirred for 8h at 
r.t., and concentrated in vacuo. The crude mixture was purified by reverse-phase HPLC [column: Luna® 
(C18, 10 m, 100 Å, 250 x 10 mm), solvents: 65:35 MeOH:H2O, flow rate: 3.0 mL/min, UV: 254 nm, 
retention time: 15 min] to afford I-CPPA (10, 3.6 mg, 63% for 3 steps): 1H NMR (400 MHz, Methanol-d4) 
δ 8.04 (d, J = 8.1 Hz, 1H), 7.23 (d, J = 8.4 Hz, 2H), 7.19 (d, J = 8.7 Hz, 2H), 7.03 (d, J = 9.1 Hz, 2H), 6.98 
(d, J = 8.5 Hz, 2H), 5.94 (d, J = 3.6 Hz, 1H), 5.74 (d, J = 8.1 Hz, 1H), 5.72 (d, J = 8.1 Hz, 1H), 5.06 (s, 1H), 
4.59 – 4.52 (m, 2H), 4.43 – 4.38 (m, 1H), 4.28 (t, J = 5.4 Hz, 1H), 4.25 (t, J = 4.4 Hz, 1H), 4.21 (d, J = 1.5 
Hz, 1H), 4.14 (dd, J = 8.3, 4.9 Hz, 1H), 3.88 – 3.85 (m, 2H), 3.82 (d, J = 8.2 Hz, 2H), 3.53 (s, 3H), 3.13 
(ddd, J = 12.3, 8.7, 3.3 Hz, 2H), 2.11 (d, J = 9.7 Hz, 3H), 1.87 (ddt, J = 13.3, 8.9, 4.1 Hz, 3H); 13C NMR 
(101 MHz, MeOD) δ 173.92, 165.98, 162.46, 157.87, 151.93, 143.90, 140.73, 130.53, 129.43 (2C), 123.29 
(2C), 118.10 (2C), 117.87 (2C), 109.98, 103.08, 100.53, 91.27, 83.47, 80.53, 78.03, 74.70, 73.54, 67.84, 
63.75, 58.42, 57.46, 48.20, 43.48 (2C), 31.49 (2C); HRMS (ESI+) m/z calcd for C36H43N3F5O12 [M + H] 
794.2860, found 794.2885. 
(2S,3S,4S)-2-((1R)-2-Amino-1-((2S,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-hydroxy-3-
methoxytetrahydrofuran-2-yl)-2-oxoethoxy)-3,4-dihydroxy-3,4-dihydro-2H-pyran-6-carboxylic acid 
(A-500359F). A solution of 32 (18 mg, 29 mol) in a 5:1 mixture of MeOH and Et3N (0.5 mL) was stirred 
for 5h at r.t., and concentrated in vacuo. The crude mixture was purified by reverse-phase HPLC [column: 
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Luna® (C18, 10 m, 100 Å, 250 x 10 mm), solvents: 15:85 MeOH:H2O, flow rate: 3.0 mL/min, UV: 254 
nm, retention time: 14 min] to afford A-500359F (12 mg, 96%): 1H NMR (400 MHz, Deuterium Oxide) δ 
7.75 (d, J = 8.1 Hz, 1H), 5.88 (d, J = 8.1 Hz, 1H), 5.80 (dd, J = 2.5, 1.6 Hz, 1H), 5.78 (d, J = 4.0 Hz, 1H), 
5.25 (d, J = 3.2 Hz, 1H), 4.71 (d, J = 2.1 Hz, 1H), 4.48 (dd, J = 5.7, 2.1 Hz, 1H), 4.43 (dd, J = 4.5, 2.5 Hz, 
1H), 4.30 (dd, J = 5.1, 4.0 Hz, 1H), 4.12 (ddd, J = 4.8, 3.3, 1.7 Hz, 1H), 3.73 (t, J = 5.4 Hz, 1H), 3.35 (s, 
3H); 13C NMR (101 MHz, D2O) δ 173.32, 168.26, 166.06, 151.29, 144.11, 140.79, 108.44, 101.93, 98.62, 
89.42, 81.99, 78.20, 75.00, 72.10, 64.43, 62.19, 57.93; HRMS (ESI+) m/z calcd for C17H22N3O12 [M + H] 
460.1204, found 460.1215. 
Synthesis of CPPB (5) in Scheme 4. To a stirred solution of A-500359F (11 mg, 0.024 mmol), 34 (26 
mg, 0.072 mmol), Glyceroacetonide-Oxyma (16 mg, 0.072 mmol)54 and NMM (26 mL, 0.24 mmol) in DMF 
(0.49 mL) was added EDCI (23 mg, 0.12 mmol). After being stirred for 5h at r.t., the reaction mixture was 
filtered, and diluted with water. The product was extracted with CHCl3/MeOH (9/1). The combined extracts 
were derived over Na2SO4, and concentrated in vacuo. The crude mixture was purified by DOWEX 50Wx4 
(MeOH : NH4OH = 4 : 1) followed by reverse-phase HPLC [column: Luna (C18, 10 mm, 100 Å, 250 x 10 
mm), solvents: 65:35 MeOH : H2O, flow rate: 3.0 mL/min, UV: 254 nm, retention time: 18 min] to afford 
5 (17 mg, 92%). All physical data were identical to that of CPPB synthesized in Scheme 3A. 
Expression and purification of HyMraY. The gene mraY of Hydrogenivirga spp. 128-5-R1-1 was 
cloned with a N-terminal His6 tag into a pET22b vector. The plasmid was transformed and expressed in E. 
coli NiCo21(DE3) pLEMO competent cells. The proteins were purified using a nickel, cation exchange, 
and size exclusion chromatography. The final storage buffer was 20 mM HEPES pH 7.5, 100 mM NaCl, 
10% glycerol, 5 mM βME, 0.15% decyl β-D-maltopyranoside (DM).  
Expression and purification of MjAglH. The gene mj1113 of Methanocaldococcus jannaschii DSM 
2661 was cloned with a N-terminal His9 tag into a pET33b-derived vector. The plasmid was transformed 
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and expressed in E. coli NiCo21(DE3) pLEMO competent cells. The proteins were purified using cobalt 
and size exclusion chromatography. The final storage buffer was 20 mM Tris-HCl, pH 7.5, 100 mM NaCl, 
5% glycerol, 5 mM βME, 0.15% DM. 
Preparation of membrane fraction P-60 containing WecA. E. coli B21 wecA strain were harvested by 
centrifugation (4,700 rpm) at 4 oC followed by washing with 0.9% saline solution (thrice).9,58 The washed 
cell pellets were washed with homogenization buffer (containing 50 mM K2HPO4, 5 mM MgCl2, 5 mM 1,4-
dithio-DL-threitol, and 10% glycerol, pH = 7.2) (thrice), and approximately 5 g of pellet (wet weight) was 
collected. The washed cell pellets were suspended in homogenization buffer and disrupted by probe 
sonication on ice (5sec on and 2sec off for 1 min, then cool down for 1.5min, 5 cycles, cool down for 15min, 
and then, 5sec on and 2sec off for 1min, cool down for 1.5min, 5 cycles). The resulting suspension was 
centrifuged at 4,700 xg for 15min at 4 oC to remove unbroken cells. The lysate was centrifuged at 25,000 
xg for 20min. at 4 oC. The supernatant was subjected to ultracentrifugation at 60,000 xg for 1h at 4 oC. The 
supernatant was discarded, and the membrane fraction containing WecA enzyme (P-60) was suspended in 
the Tris-HCl buffer (pH = 7.5). Total protein concentrations were approximately 8 to 10 mg/mL. Aliquots 
were stored in Eppendorf tubes at -80 oC. 
DPAGT1 expression and purification. DPAGT1 was expressed in suspended Expi293 cells for 36h. 
The cells were lysed by drawing through a 26g needle (10 times) and membrane protein was extracted using 
buffer containing 1% decyl β-D-maltopyranoside detergent. DPAGT1 was purified using HA-agarose resin 
and a superdex 200 size exclusion column.  
MraY assay. MraY assay substrates, Park’s nucleotide-Nε-C6-dansylthiourea, neryl phosphate, were 
chemically synthesized according to the reported procedures.7 Park’s nucleotide-Nε-C6-dansylthiourea (2 
mM stock solution, 1.88 μL), MgCl2 (0.5 M, 5 μL), KCl (2 M, 5 μL), Triton X100 (0.5%, 5.63 μL), Tris-
HCl buffer (pH 8.0, 50 mM), neryl phosphate (0.1 M, 2.25 μL), and inhibitor molecule (0 - 50 g/mL in 
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Tris-HCl buffer) were placed in a 1.5 mL Eppendorf tube. To a reaction mixture, P-60 (10μL) was added 
(total volume of reaction mixture: 50 μL adjust with Tris-HCl buffer). The reaction mixture was incubated 
for 2h at r.t. (26 oC) and quenched with CHCl3 (100 μL). Two phases were mixed via vortex and centrifuged 
at 25,000 xg for 10min. The aqueous phase was assayed via reverse-phase HPLC. The water phase (10 μL) 
was injected into HPLC (solvent: CH3CN/0.05 M aq. NH4HCO3 = 25:75; UV: 350 nm; flow rate: 0.5 
mL/min; column: Kinetex 5μm C8, 100 A, 150 x 4.60 mm), and the area of the peak for lipid I-neryl 
derivative was quantified to obtain the IC50 value. The IC50 values were calculated from plots of the 
percentage product inhibition versus the inhibitor. 
WecA assay. WecA assay substrate, UDP-Glucosamine-C6-FITC was chemically synthesized according 
to the reported procedures.9,11,59 UDP-Glucosamine-C6-FITC (UDP-GlcN-C6-FITC, 2 mM stock solution, 
0.56 L), MgCl2 (0.5 M, 4 L), -mercaptoethanol (50 mM, 5 L), CHAPS (5%, 11.3 L), Tris-HCl buffer 
(pH 8.0, 50 mM), undecaprenyl phosphate (4 mM, 1.4 L), and inhibitor molecue (0 - 50 g/mL in Tris-
HCl buffer) were place in a 1.5L Eppendorf tube. To a reaction mixture, P-60 (10 L) was added (total 
volume of reaction mixture: 50 L adjust with Tris-HCl buffer). The reaction mixture was incubated for 2h 
at 37 oC and quenched with n-butanol (150 L). Two phases were mixed via vortex and centrifuged at 
10,000 xg for 3min. The upper organic phase was assayed via reverse-phase HPLC. The organic phase (30 
L) was injected into HPLC (solvent: gradient elution of 85:15 to 95:5 MeOH/0.05 M aq. NH4HCO3; UV: 
485 nm; flow rate: 0.5 ml/ min; column: Kinetex 5 m C8, 100 Å, 150 x 4.60 mm), and the area of the peak 
for C55-P-P-GlcN-C6-FITC was quantified to obtain the IC50 value. The IC50 values were calculated from 
plots of the percentage product inhibition versus the inhibitor concentration. 
AglH assay. AglH assays were performed as the procedure described for WecA assays, but used MjAglH 
and -dihydroundecaprenyl phosphate (C55-dolichyl phosphate) instead of WecA and undecaprenyl 
phosphate. UDP-GlcN-C6-FITC (2 mM stock solution, 0.56 L), MgCl2 (0.5 M, 4 L), -mercaptoethanol 
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(50 mM, 5 L), CHAPS (5%, 11.3 L), Tris-HCl buffer (pH 8.0, 50 mM), C55-dolichyl phosphate (4 mM, 
1.4 L), and inhibitor molecule (0 - 50 g/mL in Tris-HCl buffer) were place in a 1.5L Eppendorf tube. 
To a reaction mixture, AglH solution (10 L) was added (total volume of reaction mixture: 50 L adjust 
with Tris-HCl buffer). The reaction mixture was incubated for 2h at 37 oC and quenched with n-butanol 
(150 L). Two phases were mixed via vortex and centrifuged at 10,000 xg for 3min. The upper organic 
phase was assayed via reverse-phase HPLC. The organic phase (30 L) was injected into HPLC (solvent: 
gradient elution of 85:15 to 95:5 MeOH/0.05 M aq. NH4HCO3; UV: 485 nm; flow rate: 0.5 ml/ min; column: 
Kinetex 5 m C8, 100 Å, 150 x 4.60 mm), and the area of the peak for C55-P-P-GlcN-C6-FITC was 
quantified to obtain the IC50 value. The IC50 values were calculated from plots of the percentage product 
inhibition versus the inhibitor concentration. 
DPAGT1 assay. DPAGT1 assays were performed as the procedure described for AglH assays, but used 
DPAGT1.  
Cell lines. The human primary PDAC cell lines PANC-1 (ATCC CRL 1469); Capan-2 (ATCC HTB-80) 
and metastatic PDAC cell lines Capan-1 (ATCC HTB-79), AsPC-1 (ATCC CRL-1682), L1210 ( ATCC 
CCL-219), KB (ATCC CCL-17), HeLa, SiHa (ATCC HTB-35), HCT-116 (ATCC CCL-247), DLD-1 
(ATCC CCL221), hTERT-HPNE (ATCC CRL-4023), Vero (ATCC CCL-81) were purchased from the 
ATCC. The cell lines were cultured and maintained in the media as recommended by the supplier. The cell 
lines were regularly tested for mycoplasma contamination and authenticated. In addition to ATCC cell lines, 
Dr. Glazer’s lab generated patient-derived PDAC cell line, PD002. PD002 Cells were maintained and 
cultured in DMEM medium supplemented with 20% FBS and 100 IU/mL penicillin and incubated at 37C 
with 5% CO2. 
MTT cytotoxicity assay. To study the effect of treatment with DPAGT1 inhibitors on the growth and 
proliferation of cells, a fixed number of cells (5 x 104 cells/well, 196 L) were plated in a 96 well plate. Into 
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each well 5 L of drug concentration was added. After 72h of incubation with drugs at 37 °C, 5% CO2, 10 
L of MTT solution (5 mg/mL in PBS) was added and incubated another 3h at 37 °C, 5% CO2. The medium 
was removed, and DMSO (200 L/well) was added. Viability was assessed on the basis of cellular 
conversion of MTT into a purple formazan product. The absorbance of the colored formazan product was 
measured at 570 nm by BioTek Synergy HT Spectrophotometer.  
Kinetic proliferation assay. To study the effect of treatment with DPAGT1 inhibitors on the growth and 
proliferation of cells, a fixed number of cells (2 x 104) were plated in multiple wells of a 96 well plate, 
incubated for 24h to let cells settle down. Then, CPPB (5) was added (0-50 M). Images were obtained 
every 4h using an IncuCyte Live-Cell Imaging System (Essen BioScience, Ann Arbor, MI). After 72h, cell 
proliferation was quantified using the metric phase object confluence (POC), a measurement of the area of 
the field of view that is covered by cells, which is calculated by the integrated software.  
Scratch assay. A confluent monolayer was formed in 24-well plates. The monolayer was scratched by a 
sterile 200 L pipette tip and washed with PBS to remove cell debris. Complete medium with CPPB (5) (0, 
0.05, 0.1, 0.2 M) were added and scratched areas were photographed with microscope. The scratched cells 
were incubated at 37 °C, 5% CO2. After 24h, medium was removed and cells were stained with a 1:1 mixture 
of crystal violet and PBS for 5min, washed with PBS twice, and photographed with microscope. Wound 
areas were measured and recovered areas were calculated. 
Cell migration assays using transwell chamber. Cell migration assay was performed using Boyden 
chamber (Thermo Fisher). PD002 cells (~104 cells/mL) were seeded in 96-wells plate (Corning, HTS 
Transwell-96 Well Permeable Supports, pore size: 8 μm) in FBS free media and the lower chambers were 
filled with 10% FBS medium. CPPB, tunicamycin, or gemcitabine (0.1 M) was added to the upper 
chamber. The cells were incubated for 18h at 37°C under 5% CO2. The cells were fixed using 4% 
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paraformaldehyde for 0.5h and stained with 0.05% crystal violet (300 L/well), after 0.5h, images were 
captured via 10X magnification microscopy. 
Reagents, antibodies, and cell treatments. All the primary and secondary antibodies used were obtained 
from Cell Signaling Technology. 
SDS-PAGE and Western blotting assay. The medium of the cells grown in 10 cm cell culture plate was 
removed, and the cells were washed once with PBS, and lysed with Pierce RIPA buffer (Theomo Scientific, 
Cat. # 89901) containing 1x Pierce protease and phosphatase inhibitors (Thermo Scientific, Cat. # 88668). 
The cell lysate was pelleted down at 15,200 xg at 4 oC for 15min, the cell supernatant was transferred to a 
fresh Eppendorf tube, and 5 uL of sample was quantitated by using (Quick Start Bradford Dyed Reagent, 
Biorad, Cat. # 500-0205). 50 g of each protein sample was analyzed by SDS-PAGE (10% gel) followed 
by Western blotting, and autoradiography. Precision Plus Dual Color (Biorad, Cat. # 161-0374) was used 
as protein standard marker. Clarity Western ECL Substrate (Biorad, Cat. # 170-5060) was used to develop 
the probe signal, and Classic Blue BX film (MidSci, Ref. # 604 5983) was used for autoradiography.  
Immunofluorescent staining. A confluent monolayer was formed in Nunc™ Lab-Tek™ II CC2™ 
chamber slide (8 well, Thermo Scientific, Cat. # 154941PK). Complete medium with CPPB (5, 0-20 M) 
was added and incubated at 37 °C under 5% CO2. After 24h, medium was removed and cells were washed 
with PBS (3 times), then fixed with 4% paraformaldehyde in PBS for 0.5h at 4 °C. After washing with 0.2% 
Tween-20/PBS (3 times), the cells were treated with a blocking buffer (0.2% Tween-20, 1% NGS, 1% BSA 
in PBS) for 2h at 4 °C. The cells were treated with primary antibody in blocking buffer (0.4% v/v) for 12h 
at 4 °C. The cells were washed with 0.2% Tween-20 in PBS (3 times) and treated with secondary antibody 
(Donkey anti-Rabbit IgG (H+L) Highly Cross-Adsorbed Secondary Antibody, Alexa Fluor 555 (Invitrogen, 
Cat. # A31572)) in blocking buffer (0.2% v/v) for 2h at r.t. in the dark. After additional washing (3 times) 
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with 0.2% Tween-20/PBS, the cells were treated with DAPI Fluoromount-G® (SouthernBiotech, Cat. # 
0100-20) and covered with glass slide for fluorescence microscopy analysis. 
Reverse transcription‐quantitative polymerase chain reaction (RT‐qPCR). Total RNA was extracted 
from PD002 (~106) cells using a RNeasy Mini kit (Qiagen, Inc., Valencia, CA, USA) after the treatment 
with CPPB or tunicamycin (0-10 M) for 24h. Expression was measured by Kapa probe fast qPCR Master 
Mix (2X) (KAPA BIOSYSTEMS; Wilmington, MA, USA) with S19 as an endogenous control. Primer 
sequences were as follow; DPAGT1, forward, 5'‐tcagggacaaagagatctgga‐3'; reverse, 5'‐
cagcatggtttgttctaatgctt‐3'. The PCR cycling conditions were performed with total 45 cycles at 95 oC for 
10sec and 60 oC for 10sec, 72 oC for 10sec, and cooled down at 40 oC for 30sec. Relative mRNA expression 
changes were calculated by the 2-ΔΔCq method.  
Synergistic effect of CPPB with paclitaxel. The synergistic or antagonistic activities of CPPB (5) with 
paclitaxel were assessed in vitro via micro dilution broth checkerboard technique.48 PD002 cells (180 L, 
1x104/mL) were places in each well of a 96well plate. The cells were treated with a combination of CPPB 
(0-50 M) and paclitaxel (5-0.024 M), and cultured at 37 oC for 72h under 5% CO2. Antiproliferation 
kinetic of each well were monitored by using an IncuCyte Live-Cell Imaging System (Essen BioScience, 
Ann Arbor, MI). At the endpoint, MTT assays were performed. The FIC index was calculated according to 
the following equation. ΣFIC=FICA+FICB=CA/MICA+CB/MICB where, MICA and MICB: MIC of drugs A 
and B, CA and CB=concentrations of drugs A and B used in combination. In these interaction studies, ΣFIC 
of less than 0.5 represents synergistic activity. 
Computational methods – DPAGT1 inhibitor study. Protein preparation: All molecular modeling and 
docking studies were performed using the experimental structure of the human GPT (DPAGT1, H129 
variant) with bound tunicamycin (PDB 6BW6).25 The biological unit was downloaded and prepared using 
the Protein Preparation Wizard of the Maestro Small Molecule Drug Discovery Suite (Schrödinger, LLC).49 
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Hydrogens were added, when applicable, and protonation and tautomeric states were assigned using the 
Epic program.60 Lone waters were removed and the protein was refined by optimizing H-bond assignments 
and performing a restrained minimization using MacroModel.50 Docking site preparation: The docking 
receptor grid was prepared using Schrödinger’s Glide program.51,61 The docking grid was defined as 25 Å 
region centroid of the bound tunicamycin compound. Van der Waals radius scaling was employed with a 
scaling factor of 1.0 and partial charge cutoff of 0.25 (default values). No docking constraints or excluded 
volumes were defined. Hydroxyl and thiol groups within close proximity to the bound tunicamycin 
compound (≤ 3Å) were defined as rotatable. Inhibitor docking: Compounds were built and prepared for 
docking using the LigPrep program using default settings (Schrödinger, LLC). The DPAGT1 inhibitors, 
non-inhibitors, and weak inhibitor reported herein were docked into the prepared protein using 
Schrödinger’s Glide program using XP (extra precision) settings using the grid described above.62 Glide XP 
score for CPPB (5), I-CPPB (6), CPPA (9), I-CPPA (10), OM-CPPB (7), DM-CPPB (8), I-CAP (10), OM-
CAP (2), and CAP (1) are summarized in Table S1 in Supporting Information.  
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ABBREVIATIONS 
THF, tetrahydrofuran; CH2Cl2, methylene chloride; DMSO, dimethyl sulfoxide; DMF, N,N-
dimethylformamide; MeOH, methanol; EtOH, ethanol; iPrOH, isopropanol; tBuOH, tert-butanol; EtOAc, 
ethyl acetate; CHCl3, chloroform; HRMS, high resolution mass spectrometry; HPLC, high performance 
liquid chromatography; TLC, thin layer chromatography; Bu, n-butyl; Ts, p-toluenesulfonyl; DMAP, N,N-
dimethyl-4-aminopyridine; Boc, tert-butoxycarbonyl; EDCI, 1-(3-dimethylaminopropyl)-3-
ethylcarbodiimide hydrochloride; AcOH, acetic acid; Et3N, triethylamine; NIS, N-iodosuccinimide; TFA, 
2,2,2-trifluoroacetic acid; MS, molecular sieve; ATCC, American type culture collection; SAR, structure–
activity relationship; MIC, minimum inhibitory concentration; FIC, fractional inhibitory concentration; 
MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; OD, optical density; PBS, phosphate-
buffered saline; FBS, fetal bovine serum; NADPH, nicotinamide adenine dinucleotide phosphate; UDP-
GlcNAc, uridine diphosphate N-acetylglucosamine; UMP, uridine monophosphate; RT-qPCR, reverse 
transcription quantitative real time polymerase chain reaction; CAP, capuramycin; OM-CAP, O-methyl 
capuramycin; DM-CAP, demethyl capuramycin; CPPB, capuramycin phenoxypiperidinylbenzylamide; I-
CPPB, iso-capuramycin phenoxypiperidinylbenzylamide; OM-CPPB, O-methyl capuramycin 
phenoxypiperidinylbenzylamide; DM-CPPB, demethyl capuramycin phenoxypiperidinylbenzylamide; 
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CPPA, capuramycin phenoxypiperidinylbenzylamine; I-CPPA, iso-capuramycin 
phenoxypiperidinylbenzylamine. 
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Scheme, Figure, and Table and Their Legends: 
Artwork 
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Figure 1.  Development of DPAGT1 Inhibitors of Capuramycin Analogues. Structures of Capuramcyin, 
O-Methyl capuramycin (OM-Cap), Capuramycin phenoxypiperidinylbenzylamide analogue (CPPB), 
Aminouridyl phenoxylpiperidinylbenzylbutanamide (APPB, Previously Reported DPAGT1 Inhibitor), and 
Tunicamycin (Reference Molecule).  
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Figure 2.  DPAGT1 in N-Glycan Biosynthesis.  
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Figure 3.  General Strategy of SAR of Capuramycin. 
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Scheme 1.  An Improved Synthesis of Capuramycin Analogues Developed in The Kurosu Lab. 
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Scheme 2.  Syntheses of iso-Capuramycin (I-CAP, 3) and Demethyl-capuramycin (DM-CAP, 4). 
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Scheme 3.  Syntheses of Capuramycin phenoxypiperidinylbenzylamine (CPPA, 9) and iso-Capuramycin 
phenoxypiperidinylbenzylamine (I-CPPA, 10). 
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Table 1.  Phosphotransferase Enzyme Inhibitory Activities of Capuramycin Analogues.a 
 
Entry 
 
Compound 
IC50 (M)
a 
MraY 
(Hydrogenivirga sp.) 
WecA 
(E. coli) 
AglH 
(M. jannaschii) 
DPAGT1 
(Human) 
1 Capuramycin  
(CAP, 1) 
0.13 >50 >50 >50 
2 O-Methyl capuramycin  
(OM-CAP, 2) 
>50 0.060 2.5 4.5 
3 iso-Capuramycin  
(I-CAP, 3) 
8.5 30.0 20.0 11.5 
4 Demethyl capuramycin  
(DM-CAP, 4) 
>50 35.0 >50 >50 
5 Capuramycin phenoxypiperidinylbenzylamide  
(CPPB, 5) 
10.3 0.10 0.15 0.20 
6 iso-Capuramycin phenoxypiperidinylbenzylamide  
(I-CPPB, 6) 
>50 20.0 15.0 0.60 
7 O-Methyl capuramycin 
phenoxypiperidinylbenzylamide (OM-CPPB, 7) 
5.0 10.0 30.0 20.0 
8 Demethyl capuramycin 
phenoxypiperidinylbenzylamide (DM-CPPB, 8) 
>50 30.0 >50 >50 
9 Capuramycin phenoxypiperidinylbenzylamine  
(CPPA, 9) 
>50 >50 >50 >50 
10 iso-Capuramycin phenoxypiperidinylbenzylamine  
(I-CPPA, 10) 
>50 >50 >50 >50 
11 Tunicamycin (11) 2.9 0.15 13.2 1.5 
 
aAll assay protocols are summarized in Experimental Section as well as SI. 
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Table 2.  Cytotoxicity of Capuramycin, Capuramycin Analogues, and Tunicamycin. 
 
Entry 
 
Compound 
IC50 (M)
a 
L1210 KB SiHa HCT-116 DLD-1 Capan-1 PANC-1 AsPC-1 PD002 HPNE Vero 
1 CAP (1) >50 >50 >50 >50 >50 >50 >50 >50 >50 >50 >50 
2 OM-CAP (2) >50 >50 >50 >50 >50 >50 >50 >50 >50 >50 >50 
3 CPPB (5) >50 35.0 15.0 15.0 25.0 30.0 35.0 25.0 35.0 >50 >50 
4 I-CPPB (6) >50 35.0 25.0 25.0 35.0 40.0 45.0 30.0 50.0 >50 >50 
5 Tunicamycin (11) 1.70 2.50 0.92 0.92 1.25 1.50 1.50 0.45 1.50 7.5 0.78 
 
CAP: Capuramycin.; OM-CAP: O-Methyl capuramycin.; CPPB: Capuramycin phenoxypiperidinylbenzylamide.; I-CCB: iso-Capuramycin 
phenoxypiperidinylbenzylamide.; L1210 (ATCC® CCL-219™): mouse lymphocytic leukemia.; KB (ATCC® CCL-17™): HeLa, human cervical carcinoma.; SiHa 
(ATCC® HTB-35™): human cervical squamous cell carcinoma.; HCT-116 (ATCC® CCL-247™): colorectal adenocarcinoma.; DLD-1 (ATCC® CCL221™): 
colorectal adenocarcinoma.; Capan-1 (ATCC® HTB-79™): pancreatic ductal adenocarcinoma.; PANC-1 (ATCC® CRL-1469™): pancreatic ductal carcinoma.; 
AsPC-1 (ATCC® CRL-1682™): pancreatic adenocarcinoma.; PD002: a pancreatic adenocarcinoma staged at T3N1M0 from a 55 years old Caucasian male in 
2011 (provided by Dr. Glazer (University of Tennessee Health Science Center).; hTERT-HPNE (ATCC® CRL-4023™): normal pancreatic ductal cell.; Vero 
(ATCC® CCL-81™): normal Cercopithecus aethiops kidney cell. 
aIC50 values were determined via MTT assay.  
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Figure 4.  Kinetic Proliferation Assays for PD002 Treated with CPPB Monitored by IncuCyte® Live Cell 
Analysis.a  
 
 
aImages were obtained every 4h using an IncuCyte Live-Cell Imaging System (Essen BioScience, Ann Arbor, MI). After 72h, cell 
proliferation was quantified using the metric phase object confluence (POC), the area of the field of view that is covered by cells (phase area 
confluence %) is calculated by the integrated software.  
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Figure 5.  Analyses of Migration inhibition of Pancreatic Cancers (PANC-1, PD002, AsPC-1, and Capan-
1), a Cervical carcinoma (SiHa), a Colorectal Adenocarcinoma (HCT-116) by Treatment with CPPB in 
Would Healing (Scratch) Assays.a 
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aAll images were acquired at 24h and these are summarized in SI (only the data for PD002 shown). P values were obtained from T score calculator.  
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Figure 6.  Cell Migration Inhibition of PD002 by Gemcitabine, Tunicamycin, and CPPB via Transwell 
Chamber.a  
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aThe cells were fixed using 4% paraformaldehyde for 0.5h and stained with 0.05% crystal violet (300 L/well), after 0.5h, the images were captured via 10X 
magnification microscopy. 
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Figure 7.  Immuno-fluorescent staining: Effect of a DPAGT1 Inhibitor, CPPB, on Snail in Pancreatic 
Cancer Cells (PD002 and PANC-1) and a Colorectal Adenocarcinoma (HCT-116). Western Blotting 
Assay for a Cervical Cancer (SiHa).a  
 
 
 
Snail
(29kDa)
-Actin
(45kDa)
 
 
aFluorescence microscopy images at 40x. The cells (1 x105-6) were treated with CPPB (0.05, 0.2, 2.0, and 20 M) or PBS for 24h. For 
immunefluorescent studies: the cells were treated with Snail (C15D3) rabbit mAb (Cell Signaling Technology), followed by Goat anti-Rabbit 
IgG (H+L) Cross-Adsorbed Secondary Antibody, Alexa FluorTM568 (red). DAPI (4′,6-diamidino-2-phenylindole), a blue fluorescent DNA 
dye, was used to mark the nucleus. 40x. For Western blotting assays: The cells were treated with Snail (C15D3) rabbit mAb (Cell Signaling 
Technology), followed by secondary antibody, horseradish peroxidase (HRP)-linked antibody (Cell Signaling Technology).  
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Figure 8.  Immunofluorescent Staining: Effect of a DPAGT1 inhibitor, CPPB, on E-Cadherin in 
Pancreatic cancer cells (PD002 and PANC-1) and a Colorectal Adenocarcinoma (HCT-116).a  
 
 
 
aFluorescence microscopy images at 20x. The cells (1 x105-6) were treated with CPPB (0.05, 0.2, 2.0, and 20 M) or PBS for 24h. The cells 
were treated with E-cadherin (4A2) mouse mAb (Cell Signaling Technology), followed by secondary antibody, goat anti-mouse IgG (H+L), 
Alexa FluorTM Plus 647 (Invitrogen). DAPI (4′,6-diamidino-2-phenylindole), a blue fluorescent DNA dye, was used to mark the nucleus. 40x  
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Figure 9.  Western blot Analyses of DPAGT1, Snail, and E-Cadherin in PD002, PANC-1, and HCT-116 
treated with CPPB.a  
 
 
 
aThe relative expression level was quantified by using Image Studio™ Lite quantification software (n = 3, p<0.001, see SI).; bAll cell lysates 
were prepared to be 1.5 mg total protein/mL by 15,200 xg, 30min at 4 oC unless indicated. CAt least three isoforms of DPAGT1 were detected.; 
dDPAGT1 was not detectable at 30 L (1.5 mg total protein /mL).; eThe cell lysate was prepared by ultracentrifugation (130,000 xg for 1h at 4 
oC). 30 L of the lysate was analyzed.  
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Figure 10.  Immunofluorescent staining: The DPAGT1 Expression Level in the Selected Cancer Cell 
Lines (PD002 and PANC-1) and a Colorectal Adenocarcinoma (HCT-116) Treated with CPPB.a  
 
 
 
aFluorescence microscopy images at 20x. The cells (1 x105-6) were treated with CPPB (0.05, 0.2, 2.0, and 20 M) or PBS for 72h. The cells 
were treated with DPAGT1 polyclonal antibody (Invitrogen, PA5-72704), followed by secondary antibody, Donkey anti-rabbit IgG (H+L), 
Alexa FluorTM 555 (red) (Invitrogen). DAPI (4′,6-diamidino-2-phenylindole), a blue fluorescent DNA dye, was used to mark the nucleus. 
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Figure 11.  RT-qPCR Analyses of DPAGT1 Expression Level in PD002 Treated with CPPB.a  
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a~5 x106 of PD002 was applied. Incubation time: 24h at 37 oC. At 10 M, tunicamycin killed PD002 in 100%.  
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Table 3.  Fractional Inhibitory Concentration (FIC) of a Combination of CPPB and Paclitaxel against a 
Patient-derived Pancreatic Adenocarcinoma PD002.a 
 
 Combination of A and Bb CA and CB (M)
c FICd 
Entry 
1 A: CPPB 0.10 0.50 
B: Paclitaxel 0.63 
2 A: CPPB 0.10 0.13 
B: Paclitaxel 0.16 
3 A: CPPB 0.20 0.0096 
B: Paclitaxel 0.0049 
4 A: CPPB 0.20 0.021 
B: Paclitaxel 0.020 
5 A: CPPB 0.20 0.26 
B: Paclitaxel 0.031 
6 A: CPPB 2.0 0.021 
B: Paclitaxel 0.020 
7 A: CPPB 2.0 0.037 
B: Paclitaxel 0.039 
8 A: CPPB 2.0 0.26 
B: Paclitaxel 0.31 

aFIC index for the wells at growth–no growth interface. bThe IC50 values of CPPB and paclitaxel against PD002 are 35.0 and 1.25 M, respectively. 
cCA and CB 
are concentrations of A and B. dFIC is the sum of fractional inhibitory concentration calculated by the equation FIC = FICA + FICB = CA/IC50A + CB/IC50B. 
Cellular behavior of PD002 treated with paclitaxel or a combination with paclitaxel and CPPB was monitored over time by IncuCyte® live cell analysis 
(Supporting Information). 
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Figure 12.  Modeling CPPB-DPAGT1 Interaction to Design New Inhibitor Molecules.a  
 
 
 
aDocking studies were performed using the human DPAGT1 with bound tunicamycin (PDB: 6BW6) (PMID 29459785). The biological unit 
was downloaded and prepared using the Protein Preparation Wizard of the Maestro Small Molecule Drug Discovery Suite (Schrödinger, 
LLC). The docking receptor grid was prepared using Schrödinger’s Glide program. (PMID 15027866, PMID 15027865). CPPB was built and 
prepared for docking using the LigPrep program using default settings (Schrödinger, LLC). A: Predicted binding pose of CPPB (highlighted 
ball & stick model) into DPAGT1. Key active site loops (yellow) and transmembrane regions (orange) are indicated. B: 2D ligand interaction 
diagram of the docked CPPB-DPAGT1 complex with key predicted interactions shown. 
CL: cytoplasmic loop.; TM: transmembrane segment 
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Scheme 4.  A Semi-synthesis of CPPB from Synthetic A-500359F, a Metabolite of S. griseus SANK60196. 
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